<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/048553</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;048553v4</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;048553</article-id><article-id pub-id-type="other" hwp:sub-type="slug">048553</article-id><article-id pub-id-type="other" hwp:sub-type="tag">048553</article-id><article-version>1.4</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Cancer Biology" hwp:journal="biorxiv"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Wild-type U2AF1 antagonizes the splicing program characteristic of U2AF1-mutant tumors and is required for cell survival</article-title></title-group><author-notes hwp:id="author-notes-1"><corresp id="cor1" hwp:id="corresp-1" hwp:rev-id="xref-corresp-1-1 xref-corresp-1-2 xref-corresp-1-3 xref-corresp-1-4"><label>*</label>Correspondence: D.L.F. <email hwp:id="email-1">dlf2002@med.cornell.edu</email>; C.L.K. <email hwp:id="email-2">clara_kielkopf@urmc.rochester.edu</email>; R.K.B. <email hwp:id="email-3">rbradley@fredhutch.org</email>; H.V. <email hwp:id="email-4">varmus@med.cornell.edu</email></corresp></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" corresp="yes" hwp:id="contrib-1"><name name-style="western" hwp:sortable="Fei Dennis Liang"><surname>Fei</surname><given-names>Dennis Liang</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-1" hwp:rel-id="aff-2">2</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-1" hwp:rel-id="corresp-1">*</xref></contrib><contrib contrib-type="author" hwp:id="contrib-2"><name name-style="western" hwp:sortable="Motowski Hayley"><surname>Motowski</surname><given-names>Hayley</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-3"><name name-style="western" hwp:sortable="Chatrikhi Rakesh"><surname>Chatrikhi</surname><given-names>Rakesh</given-names></name><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-1" hwp:rel-id="aff-3">3</xref></contrib><contrib contrib-type="author" hwp:id="contrib-4"><name name-style="western" hwp:sortable="Prasad Sameer"><surname>Prasad</surname><given-names>Sameer</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-3" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-5"><name name-style="western" hwp:sortable="Yu Jovian"><surname>Yu</surname><given-names>Jovian</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-4" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-6"><name name-style="western" hwp:sortable="Gao Shaojian"><surname>Gao</surname><given-names>Shaojian</given-names></name><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-1" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-7"><name name-style="western" hwp:sortable="Kielkopf Clara L."><surname>Kielkopf</surname><given-names>Clara L.</given-names></name><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-2" hwp:rel-id="aff-3">3</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-2" hwp:rel-id="corresp-1">*</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-8"><name name-style="western" hwp:sortable="Bradley Robert K."><surname>Bradley</surname><given-names>Robert K.</given-names></name><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-1" hwp:rel-id="aff-5">5</xref><xref ref-type="aff" rid="a6" hwp:id="xref-aff-6-1" hwp:rel-id="aff-6">6</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-3" hwp:rel-id="corresp-1">*</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-9"><name name-style="western" hwp:sortable="Varmus Harold"><surname>Varmus</surname><given-names>Harold</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-5" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-2" hwp:rel-id="aff-2">2</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-4" hwp:rel-id="corresp-1">*</xref></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2 xref-aff-1-3 xref-aff-1-4 xref-aff-1-5"><label>1</label><institution hwp:id="institution-1">Cancer Biology Section, Cancer Genetics Branch, National Human Genome Research Institute</institution>, Bethesda, MD 20892, <country>United States</country></aff><aff id="a2" hwp:id="aff-2" hwp:rev-id="xref-aff-2-1 xref-aff-2-2"><label>2</label><institution hwp:id="institution-2">Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine</institution>, New York, NY 10065, <country>United States</country></aff><aff id="a3" hwp:id="aff-3" hwp:rev-id="xref-aff-3-1 xref-aff-3-2"><label>3</label><institution hwp:id="institution-3">Department of Biochemistry and Biophysics, Center for RNA Biology, University of Rochester Medical Center</institution>, Rochester, NY 14642, <country>United States</country></aff><aff id="a4" hwp:id="aff-4" hwp:rev-id="xref-aff-4-1"><label>4</label><institution hwp:id="institution-4">Genetics Branch, National Cancer Institute</institution>, Bethesda, Maryland, 20892, <country>United States</country></aff><aff id="a5" hwp:id="aff-5" hwp:rev-id="xref-aff-5-1"><label>5</label><institution hwp:id="institution-5">Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center</institution>, Seattle, WA 98109, <country>United States</country></aff><aff id="a6" hwp:id="aff-6" hwp:rev-id="xref-aff-6-1"><label>6</label><institution hwp:id="institution-6">Basic Sciences Division, Fred Hutchinson Cancer Research Center</institution>, Seattle, Washington 98109, <country>United States</country></aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2016"><year>2016</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2016-04-13T20:39:17-07:00">
    <day>13</day><month>4</month><year>2016</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2016-05-20T10:18:20-07:00">
    <day>20</day><month>5</month><year>2016</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2016-04-13T21:57:31-07:00">
    <day>13</day><month>4</month><year>2016</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2016-05-20T10:48:53-07:00">
    <day>20</day><month>5</month><year>2016</year>
  </pub-date><elocation-id>048553</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2016-04-13"><day>13</day><month>4</month><year>2016</year></date>
<date date-type="accepted" hwp:start="2016-05-20"><day>20</day><month>5</month><year>2016</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">Â© 2016, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2016</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/" hwp:id="license-1"><p hwp:id="p-1">This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link l:rel="related" l:ref-type="uri" l:ref="http://creativecommons.org/licenses/by/4.0/" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" hwp:id="ext-link-1">http://creativecommons.org/licenses/by/4.0/</ext-link></p></license></permissions><self-uri xlink:href="048553.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/048553v4.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="048553.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2019/abstracts/048553v4/048553v4.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/048553v4/048553v4.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">Abstract</title><p hwp:id="p-2">We have asked how the common S34F mutation in the splicing factor U2AF1 regulates alternative splicing in lung cancer, and why wild-type U2AF1 is retained in cancers with this mutation. A human lung epithelial cell line was genetically modified so that <italic toggle="yes">U2AF1S34F</italic> is expressed from one of the two endogenous <italic toggle="yes">U2AF1</italic> loci. By altering levels of mutant or wild-type U2AF1 in this cell line and by analyzing published data on human lung adenocarcinomas, we show that S34F-associated changes in alternative splicing are proportional to the ratio of S34F:wild-type gene products and not to absolute levels of either the mutant or wild-type factor. Preferential recognition of specific 3' splice sites in S34F-expressing cells is largely explained by differential <italic toggle="yes">in vitro</italic> RNA-binding affinities of mutant versus wild-type U2AF1 for those same 3' splice sites. Finally, we show that lung adenocarcinoma cell lines are independent on mutant U2AF1 for growth <italic toggle="yes">in vitro</italic> or <italic toggle="yes">in vivo</italic>. In contrast, wild-type U2AF1 is required for survival, regardless of whether cells carry the <italic toggle="yes">U2AF1S34F</italic> allele. Our results provide a mechanistic explanation of the magnitude of splicing changes observed in <italic toggle="yes">U2AF1</italic>-mutant cells, and explain why tumors harboring <italic toggle="yes">U2AF1</italic> mutations always retain an expressed copy of the wild-type allele.</p></abstract><kwd-group kwd-group-type="author" hwp:id="kwd-group-1"><title hwp:id="title-2">Keywords</title><kwd hwp:id="kwd-1">U2AF1</kwd><kwd hwp:id="kwd-2">splicing factor</kwd><kwd hwp:id="kwd-3">S34F</kwd><kwd hwp:id="kwd-4">RNA binding</kwd><kwd hwp:id="kwd-5">lung adenocarcinoma</kwd></kwd-group><counts><page-count count="46"/></counts><custom-meta-wrap>
    <custom-meta hwp:id="custom-meta-1">
      <meta-name>has-earlier-version</meta-name>
      <meta-value>yes</meta-value>
    </custom-meta>
  </custom-meta-wrap></article-meta></front><body><sec id="s1" hwp:id="sec-1"><title hwp:id="title-3">Introduction</title><p hwp:id="p-3">Somatic mutations in genes encoding four splicing factors (<italic toggle="yes">U2AF1, SF3B1, SRSF2</italic> and <italic toggle="yes">ZRSR2</italic>) have recently been reported in up to 50% of myelodysplastic syndromes (MDS) and related neoplasms and at lower frequencies in a variety of solid tumors (<xref rid="c34" ref-type="bibr" hwp:id="xref-ref-34-1" hwp:rel-id="ref-34">Yoshida et al. 2011</xref>; <xref rid="c13" ref-type="bibr" hwp:id="xref-ref-13-1" hwp:rel-id="ref-13">Graubert et al. 2012</xref>; <xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">Imielinski et al. 2012</xref>; <xref rid="c12" ref-type="bibr" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">Furney et al. 2013</xref>; <xref rid="c30" ref-type="bibr" hwp:id="xref-ref-30-1" hwp:rel-id="ref-30">Wang et al. 2011</xref>; <xref rid="c31" ref-type="bibr" hwp:id="xref-ref-31-1" hwp:rel-id="ref-31">Waterfall et al. 2014</xref>; <xref rid="c6" ref-type="bibr" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">Cancer Genome Atlas Network 2012</xref>; <xref rid="c3" ref-type="bibr" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">Biankin et al. 2012</xref>; <xref rid="c7" ref-type="bibr" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">Cancer Genome Atlas Research Network 2014</xref>). Among these factors, only <italic toggle="yes">U2AF1</italic> is recurrently mutated in lung adenocarcinomas (LUADs) (<xref rid="c15" ref-type="bibr" hwp:id="xref-ref-15-2" hwp:rel-id="ref-15">Imielinski et al. 2012</xref>; <xref rid="c7" ref-type="bibr" hwp:id="xref-ref-7-2" hwp:rel-id="ref-7">Cancer Genome Atlas Research Network 2014</xref>). The only recurrent missense mutation of <italic toggle="yes">U2AF1</italic> in LUAD affects codon 34 and always changes the conserved serine in a zinc knuckle motif to phenylalanine (p.Ser34Phe, or S34F). This striking mutational consistency suggests a critical, yet unknown, role for <italic toggle="yes">U2AF1S34F</italic> during lung carcinogenesis. In addition, the wild-type (WT) <italic toggle="yes">U2AF1</italic> allele is always retained in cancers with common <italic toggle="yes">U2AF1</italic> mutations, including <italic toggle="yes">U2AF1S34F</italic> (<xref rid="c13" ref-type="bibr" hwp:id="xref-ref-13-2" hwp:rel-id="ref-13">Graubert et al. 2012</xref>). However, the functional significance of the wild-type allele in cells with mutant <italic toggle="yes">U2AF1</italic> is not known.</p><p hwp:id="p-4">U2AF1 is a component of the U2 small nuclear ribonucleoprotein auxiliary factor complex (U2AF) (<xref rid="c27" ref-type="bibr" hwp:id="xref-ref-27-1" hwp:rel-id="ref-27">Ruskin et al. 1988</xref>; <xref rid="c36" ref-type="bibr" hwp:id="xref-ref-36-1" hwp:rel-id="ref-36">Zamore and Green 1989</xref>). During early spliceosome assembly, U2AF recognizes sequences at the 3' ends of introns to facilitate the recruitment of U2 small nuclear ribonucleoprotein (snRNP) to the 3' splice site; the recruitment occurs in conjunction with recognition of the intronic branch point by splicing factor 1 (SF1) (<xref rid="c17" ref-type="bibr" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">KrÃ¤mer and Utans 1991</xref>; <xref rid="c2" ref-type="bibr" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">Berglund et al. 1998</xref>). <italic toggle="yes">In vitro</italic> crosslinking assays showed that U2AF1 contacts the AG dinucleotide at the intron-exon boundary and flanking sequences (<xref rid="c21" ref-type="bibr" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">Merendino et al. 1999</xref>; <xref rid="c32" ref-type="bibr" hwp:id="xref-ref-32-1" hwp:rel-id="ref-32">Wu et al. 1999</xref>; <xref rid="c38" ref-type="bibr" hwp:id="xref-ref-38-1" hwp:rel-id="ref-38">Zorio and Blumenthal 1999</xref>).</p><p hwp:id="p-5">Consistent with the critical role that U2AF1 plays in RNA splicing, <italic toggle="yes">U2AF1</italic> mutations are known to cause specific alterations in RNA splicing, most notably affecting the inclusion of cassette exons in mRNA (<xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">Ilagan et al. 2015</xref>; <xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">Okeyo-Owuor et al. 2015</xref>; <xref rid="c4" ref-type="bibr" hwp:id="xref-ref-4-1" hwp:rel-id="ref-4">Brooks et al. 2014</xref>; <xref rid="c25" ref-type="bibr" hwp:id="xref-ref-25-1" hwp:rel-id="ref-25">Przychodzen et al. 2013</xref>). However, the precise molecular basis of these splicing alterations, as well as how they are quantitatively regulated, is unknown. One possibility is that U2AF1 mutations cause altered RNA-binding affinity, resulting in altered splice site recognition. A computational model of the structure of the U2AF1:RNA complex suggested that Ser34 is a critical residue that contacts RNA (<xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-2" hwp:rel-id="ref-14">Ilagan et al. 2015</xref>). Another study reported that U2AF1S34F exhibited altered affinity relative to the wild-type protein for RNA oligonucleotides derived from a cassette exon whose recognition is repressed in S34F-expressing cells (<xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-2" hwp:rel-id="ref-23">Okeyo-Owuor et al. 2015</xref>). Finally, the S34F mutation reportedly prevented a minimal fission yeast U2AF heterodimer from binding to a particular 3' splice site RNA sequence (<xref rid="c33" ref-type="bibr" hwp:id="xref-ref-33-1" hwp:rel-id="ref-33">Yoshida et al. 2015</xref>). However, it is not known whether altered RNA binding accounts for most S34F-associated splicing alterations and whether mechanisms other than altered binding control S34F-associated splicing.</p><p hwp:id="p-6">Here, we combine genetic and biochemical approaches to show that wild-type U2AF1 antagonizes the S34F-associated splicing program in lung epithelial cells. Analyses of the transcriptomes of primary LUAD samples as well as isogenic lung cells in culture indicate that the ratio of mutant to wild-type U2AF1 gene products is a critical determinant of the magnitude of S34F-associated changes in alternative splicing. S34F-associated splicing alterations can be largely explained by differences in the relative affinities of U2AF-SF1 complexes containing mutant versus wild-type U2AF1 for RNA containing the relevant 3' splice sites. Moreover, we show that proliferation of cancer cells with <italic toggle="yes">U2AF1S34F</italic> is critically dependent on expression of the wild-type, but not the mutant, allele of <italic toggle="yes">U2AF1</italic>.</p></sec><sec id="s2" hwp:id="sec-2"><title hwp:id="title-4">Results</title><sec id="s2a" hwp:id="sec-3"><title hwp:id="title-5">S34F-associated splicing correlates with S34F:WT mRNA ratios in LUAD</title><p hwp:id="p-7">Before undertaking experiments to study the effects of mutant U2AF1 in cultured cells, we first examined 512 transcriptomes from primary human LUADs published by The Cancer Genome Atlas (TCGA) (<xref rid="c7" ref-type="bibr" hwp:id="xref-ref-7-3" hwp:rel-id="ref-7">Cancer Genome Atlas Research Network 2014</xref>). Thirteen of these tumors harbor the most common <italic toggle="yes">U2AF1</italic> mutation, S34F. (Two others carry rare mutations of unknown significance, S65L and G216R, and were not considered further.) We identified cassette exons whose inclusion was increased or decreased by ten percent or more in each tumor with the S34F mutation relative to the median inclusion of each cassette exon across all of tumors without a <italic toggle="yes">U2AF1</italic> mutation. We then identified consensus sequence motifs for the 3' splice sites lying immediately upstream of the cassette exons that were promoted or repressed in association with U2AF1S34F, represented by âsequence logosâ as shown in <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Figs. 1A</xref> and S1. The same analysis was performed on 19 random tumors lacking a <italic toggle="yes">U2AF1</italic> mutation as controls.</p><fig id="fig1" position="float" fig-type="figure" orientation="portrait" hwp:id="F1" hwp:rev-id="xref-fig-1-1 xref-fig-1-2 xref-fig-1-3 xref-fig-1-4 xref-fig-1-5 xref-fig-1-6 xref-fig-1-7 xref-fig-1-8 xref-fig-1-9 xref-fig-1-10 xref-fig-1-11"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;048553v4/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Fig. 1.</label><caption hwp:id="caption-1"><p hwp:id="p-8"><bold>S34F-associated splicing correlates with S34F:WT mRNA ratios in LUAD</bold>. (A). Different consensus 3' splice site sequences preceding cassette exons for two representative LUADs with the S34F mutation computed from published TCGA transcriptomes. In both cases, changes in the use of cassette exons were determined by comparisons with an average transcriptome from LUADs without <italic toggle="yes">U2AF1</italic> mutations. Boxes highlight nucleotides found preferentially at the â3 position. The nucleotide frequencies preceding exons that are more often included or more often excluded in tumors with the S34F mutation differ from the genomic consensus in the tumor from patient #7903, which represent âtypical S34Fâ consensus 3' splice sites, but not in the tumor from patient #7727, which represent âquasi-WTâ consensus 3' splice sites. (Consensus 3' splice sites from transcriptomes of every S34F-mutant LUAD are presented in Supplemental Fig. S1.) The analysis was restricted to introns with canonical GT-AG U2-type splice sites. The vertical axis represents the information content in bits. n is the number of cassette exon sequences used to construct the logo. The scheme of alternative splicing with a cassette exon (black box) is shown on the left side of the sequence logo. Black lines represent S34F-promoted splices. (B). U2AF1 mutant LUAD transcriptomes harboring âtypical S34Fâ consensus 3' splice sites have relatively high S34F:WT mRNA ratios. U2AF1 mutant LUAD samples were grouped based on the nature of the consensus 3' splice sites. The asterisk represents a statistically significant change by student's t test (p value &lt; 0.05). (C). S34F:WT mRNA ratios do not correlate with tumor purity in LUAD tumors with the S34F mutation. Tumor purity is represented by the percent of tumor nuclei in each LUAD sample (derived from TCGA clinical data) and plotted against the S34F:WT mRNA ratios. The r<sup>2</sup> value of linear regression is shown. (D). Inclusion of the <italic toggle="yes">STRAP</italic> cassette exon correlates with the S34F:WT mRNA ratio. The twelve mutant LUAD transcriptomes in the TCGA database with a sufficient number of informative reads to calculate the inclusion frequency for the <italic toggle="yes">STRAP</italic> cassette exon are represented as black dots. The median inclusion level of the same cassette exon for all transcriptomes from tumors without the mutation is shown as a grey dot near the ordinate axis. r, Pearson's association coefficient.</p></caption><graphic xlink:href="048553_fig1" position="float" orientation="portrait" hwp:id="graphic-1"/></fig><p hwp:id="p-9">As illustrated by data from patient 7903 in <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-2" hwp:rel-id="F1">Fig. 1A</xref>, over two hundred cassette exons were included more frequently and a similar number were included less frequently in this <italic toggle="yes">U2AF1</italic>-mutant tumor. Notably, as illustrated by the sequence logos, the nucleotide distribution at the â3 position (boxed) of promoted and repressed exons was different from that observed upstream of the much larger number of unaffected exons: A replaced T as the second most common nucleotide preceding the promoted exons, while T was more common than C in the sequence preceding the repressed exons. These patterns were observed in nine of the thirteen tumors with the <italic toggle="yes">U2AF1S34F</italic> allele (Supplemental Fig. S1A). They have been observed previously in comparisons between transcriptomes carrying the <italic toggle="yes">U2AF1S34F</italic> allele with wild-type transcriptomes (<xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-3" hwp:rel-id="ref-14">Ilagan et al. 2015</xref>; <xref rid="c4" ref-type="bibr" hwp:id="xref-ref-4-2" hwp:rel-id="ref-4">Brooks et al. 2014</xref>; <xref rid="c25" ref-type="bibr" hwp:id="xref-ref-25-2" hwp:rel-id="ref-25">Przychodzen et al. 2013</xref>; <xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-3" hwp:rel-id="ref-23">Okeyo-Owuor et al. 2015</xref>), and are therefore henceforth referred to as the âtypical S34Fâ consensus 3' splice sites. In the other four tumors with the <italic toggle="yes">U2AF1S34F</italic> mutant, these âtypical S34Fâ consensus 3' splice sites were partially or completely absent (Supplemental Fig. S1B). Those four tumors exhibited consensus 3' splice sites that were similar to the consensus 3' splice sites identified in tumors lacking a <italic toggle="yes">U2AF1</italic> mutation, where variations in inclusion relative to the median wild-type sample are presumably stochastic (Supplemental Fig. S1C). Thus, we henceforth refer to these sequence patterns, as shown for tumor from patient 7727 in <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-3" hwp:rel-id="F1">Fig. 1A</xref>, as âquasi-WTâ.</p><p hwp:id="p-10">To explain why transcriptomes of some tumors with <italic toggle="yes">U2AF1</italic> mutations showed a typical S34F-associated consensus 3' splice sites, while others exhibited quasi-WT patterns, we estimated the levels of mutant and total <italic toggle="yes">U2AF1</italic> mRNA based on available data from the tumors to determine the ratio of mutant to wild-type (S34F:WT) mRNA. Tumors with quasi-WT patterns had low S34F:WT mRNA ratios (ranging from 0.27 to 0.31), whereas all but one tumor with the S34F-associated pattern had a higher ratio (0.43 or more) (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-4" hwp:rel-id="F1">Fig. 1B</xref>). In contrast, absolute levels of <italic toggle="yes">U2AF1S34F</italic> mRNA or total <italic toggle="yes">U2AF1</italic> mRNA levels were not different between these two groups of tumors (Supplemental Figs. S2A, B).</p><p hwp:id="p-11">We next sought to understand the origin of the wide range of S34F:WT ratios that we observed. These ratios, ranging from 0.26 to 0.82, could not be explained by contamination of tumor cells with non-tumor cells, since the proportion of tumor nuclei reported for these samples did not correlate with S34F:WT mRNA ratios (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-5" hwp:rel-id="F1">Fig. 1C</xref>) or with the presence or absence of the expected S34F-associated consensus 3' splice sites (Supplemental Fig. S2C). Conversely, <italic toggle="yes">U2AF1</italic> DNA copy number correlated with the estimated levels of total <italic toggle="yes">U2AF1</italic> mRNA (Supplemental Fig. S2D). Seven of the 13 <italic toggle="yes">U2AF1S34F</italic> mutant samples showed either copy number loss or gain at the <italic toggle="yes">U2AF1</italic> locus, suggesting that copy number variation (CNV) might account, at least in part, for the varying S34F:WT mRNA ratios in LUAD samples. Unbalanced allelic expression or proportions of tumor subclones might also contribute to the variable S34F:WT mRNA ratios, although these possibilities could not be readily tested using the available LUAD data.</p><p hwp:id="p-12">We next tested whether the <italic toggle="yes">U2AF1</italic> S34F:WT ratio was associated with quantitative changes in splicing (versus the qualitative differences in consensus 3' splice sites described above). We correlated S34F:WT ratios with the quantitative inclusion of specific S34F-responsive cassette exons that were reported previously (<xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-4" hwp:rel-id="ref-14">Ilagan et al. 2015</xref>; <xref rid="c4" ref-type="bibr" hwp:id="xref-ref-4-3" hwp:rel-id="ref-4">Brooks et al. 2014</xref>; <xref rid="c25" ref-type="bibr" hwp:id="xref-ref-25-3" hwp:rel-id="ref-25">Przychodzen et al. 2013</xref>). We studied two cassette exons that exhibited less (<italic toggle="yes">ASUN</italic> and <italic toggle="yes">STRAP</italic>) and one that exhibited more (<italic toggle="yes">ATR</italic>) inclusion in the presence of <italic toggle="yes">U2AF1S34F</italic>. Tumors with the highest S34F:WT mRNA ratios showed the lowest inclusion levels of the cassette exon in <italic toggle="yes">STRAP</italic> mRNA, whereas tumors without a <italic toggle="yes">U2AF1</italic> mutation had the highest level of inclusion (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-6" hwp:rel-id="F1">Fig. 1D</xref>; Pearson correlation of â 0.79). Similar correlations were observed between inclusion levels of the <italic toggle="yes">ASUN</italic> and <italic toggle="yes">ATR</italic> cassette exons and S34F:WT mRNA ratios (Supplemental Fig. S3E, I). As controls, we tested for correlations between the inclusion of these cassette exons and levels of <italic toggle="yes">U2AF1S34F</italic> mRNA, total <italic toggle="yes">U2AF1</italic> mRNA, or percent tumor nuclei. None of these analyses showed a relationship as strong as that observed for the S34F:WT mRNA ratio (Supplemental Figs. S3B-D, F-H, J-L). These results indicate that the S34F:WT mRNA ratio predicts the magnitude of S34F-associated splicing in human LUAD.</p></sec><sec id="s2b" hwp:id="sec-4"><title hwp:id="title-6">Creation of isogenic lung cell lines that recapitulate features of S34F-associated splicing in LUAD</title><p hwp:id="p-13">The results presented in the preceding section, based on analyses of LUAD tumors with the <italic toggle="yes">U2AF1S34F</italic> mutation, suggest that the magnitude of S34F-associated splicing is a function of the S34F:WT mRNA ratio. To directly test this hypothesis, we developed a cell line that allows manipulation of WT and mutant U2AF1 gene product levels and measurement of the corresponding effects on RNA splicing.</p><p hwp:id="p-14">The human bronchial epithelial cell line (HBEC3kt) was previously derived from normal human bronchial tissue and immortalized by introduction of expression vectors encoding human telomerase reverse transcriptase (<italic toggle="yes">hTERT</italic>) and cyclin-dependent kinase-4 (<italic toggle="yes">CDK4</italic>) (<xref rid="c26" ref-type="bibr" hwp:id="xref-ref-26-1" hwp:rel-id="ref-26">Ramirez et al. 2004</xref>). To knock in a <italic toggle="yes">U2AF1S34F</italic> allele at an endogenous locus in HBEC3kt cells, we adopted a published genomic DNA editing approach (<xref rid="c35" ref-type="bibr" hwp:id="xref-ref-35-1" hwp:rel-id="ref-35">Yusa 2013</xref>), using the <italic toggle="yes">PiggyBac</italic> transposon that leaves no traces of exogenous DNA at the locus (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Fig. 2A</xref>; see Supplemental Materials and Methods for details). We identified three cell clones at intermediate stages of gene editing after screening more than 50 primary transfectants (Supplemental Fig. S4A, B). Sanger sequencing of these intermediate clones revealed that one of the three clones carried the desired S34F missense sequence, while two clones were wild-type (Supplemental Fig. S4C). Wild-type intermediates were expected because a homologous sequence between the S34F point mutation and the drug cassette in the vector can serve as the 5' homology arm for recombination (designated as 5' HA#2 in <xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-2" hwp:rel-id="F2">Fig. 2A</xref>). From the final clones derived from these intermediates (after transposition to remove the <italic toggle="yes">PiggyBac</italic> element), we chose one subclone from each of the two wild-type intermediate clones (referred to as WT1 and WT2 cells) and two subclones from the sole mutant intermediate clone (referred to as MUT1 a and MUT1 b cells) for all subsequent experiments with isogenic HBEC3kt cells (Supplemental Fig. S4D). The MUT and WT cells all expressed similar levels of <italic toggle="yes">U2AF1</italic> mRNA and protein (Supplemental Fig. S4E). Using high-throughput mRNA sequencing (RNA-seq) and allele-specific RT-qPCR, we observed similar levels of wild-type and mutant <italic toggle="yes">U2AF1</italic> mRNAs in the MUT cells (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-3" hwp:rel-id="F2">Figs. 2B</xref>, S5), consistent with heterozygosity at the <italic toggle="yes">U2AF1</italic> locus.</p><fig id="fig2" position="float" fig-type="figure" orientation="portrait" hwp:id="F2" hwp:rev-id="xref-fig-2-1 xref-fig-2-2 xref-fig-2-3 xref-fig-2-4 xref-fig-2-5 xref-fig-2-6 xref-fig-2-7"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;048553v4/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Fig. 2.</label><caption hwp:id="caption-2"><p hwp:id="p-15"><bold>Creation of isogenic lung cell lines that recapitulate features of S34F-associated splicing</bold>. (A). Strategy to create a TCT to TTT point mutation (S34F) at the endogenous <italic toggle="yes">U2AF1</italic> locus in HBEC3kt cells. TALEN, transcription activator-like effector nuclease; E, exon; mE, mutant (S34F) exon; ITR, inverted terminal repeat; HA, homology arm. See Results and Supplemental Materials and Methods for details. (B). MUT1 a and MUT1 b cells contain similar levels of mutant and wild-type <italic toggle="yes">U2AF1</italic> mRNA. The number of reads specific for mutant and wild-type <italic toggle="yes">U2AF1</italic> was obtained from RNA-seq, using poly A-selected RNA from the four cell lines. (C). The S34F-associated cassette exons in <italic toggle="yes">ASUN</italic> and <italic toggle="yes">STRAP</italic> mRNAs showed increased exclusion in MUT cell lines. (Top) Scheme of alternative splicing with a cassette exon (black box) to generate short and long isoforms in which the cassette exon is excluded or included. (Bottom) Alternative splicing of cassette exons in <italic toggle="yes">ASUN</italic> and <italic toggle="yes">STRAP</italic> mRNAs, measured by RT-qPCR using isoform-specific primers. The short/long isoform ratio in WT1 cells was arbitrarily set to 1 for comparison. (D). Heat map depicting the inclusion levels of all cassette exons. Dendrograms were constructed from an unsupervised cluster analysis based on all cassette exons that showed at least a 10% change in use between WT and MUT cells. (E). Sequence logos from 3â splice sites preceding cassette exons with altered use in MUT1a cells display typical S34F-associated features. Logos were constructed as in <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-7" hwp:rel-id="F1">Fig. 1A</xref> based on the transcriptome of MUT1a cells in comparison with that of WT1 cells. Other comparisons of transcriptomes from MUT and WT cell lines yielded similar sequence logos (data not shown).</p></caption><graphic xlink:href="048553_fig2" position="float" orientation="portrait" hwp:id="graphic-2"/></fig><p hwp:id="p-16">To determine how the engineered <italic toggle="yes">U2AF1 S34F</italic> allele affects mRNA splicing, we first assayed the inclusion levels of 20 cassette exons that were previously reported to be associated with mutant <italic toggle="yes">U2AF1</italic> in both LUAD and AML (acute myeloid leukemia) (<xref rid="c4" ref-type="bibr" hwp:id="xref-ref-4-4" hwp:rel-id="ref-4">Brooks et al. 2014</xref>). We confirmed that all 20 of these cassette exons, which included the previously studies <italic toggle="yes">ASUN</italic> and <italic toggle="yes">STRAP</italic> cassette exons, were indeed S34F-dependent in our engineered cells using RT-qPCR with isoform-specific primers (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-4" hwp:rel-id="F2">Figs. 2C</xref>, S6).</p><p hwp:id="p-17">We next evaluated the global difference in cassette exon recognition in MUT versus WT cells using RNA-seq (Supplemental Table S1). MUT and WT cells were grouped separately in an unsupervised cluster analysis based on cassette exon inclusion (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-5" hwp:rel-id="F2">Fig. 2D</xref>). We observed the expected consensus 3' splice sites of cassette exons that were promoted or repressed in MUT versus WT cells (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-6" hwp:rel-id="F2">Fig. 2E</xref>). Overall, these results indicate that we successfully created clonal HBEC3kt cells isogenic for <italic toggle="yes">U2AF1S34F</italic> and that the MUT cells exhibited similar alterations in splicing relative to their WT counterparts as do primary LUAD transcriptomes.</p></sec><sec id="s2c" hwp:id="sec-5"><title hwp:id="title-7">The ratio of S34F:WT gene products controls S34F-associated splicing in isogenic lung cells</title><p hwp:id="p-18">We next used our isogenic cell model with the <italic toggle="yes">U2AF1S34F</italic> mutation to test the hypothesis that the S34F:WT ratio, rather than absolute levels of the mutant or wild-type gene products, controls S34F-associated splicing. We tested two specific predictions. First, changing the levels of <italic toggle="yes">U2AF1S34F</italic>, while keeping the S34F:WT ratio constant, should not affect S34F-associated splicing. Second, changing the level of wild-type <italic toggle="yes">U2AF1</italic> while keeping the level of <italic toggle="yes">U2AF1S34F</italic> constant (e.g., allowing the S34F:WT ratio to change) should alter the inclusion of S34F-dependent cassette exons. We tested these predictions in the isogenic HBEC3kt cells by manipulating levels of wild-type or mutant <italic toggle="yes">U2AF1</italic> gene products and measuring the subsequent changes in S34F-associated splicing.</p><p hwp:id="p-19">We first reduced the amounts of both mutant and wild-type <italic toggle="yes">U2AF1</italic> mRNA concordantly in MUT1a cells, keeping the S34F:WT mRNA ratio constant. This was achieved by transducing MUT1a cells with short hairpin RNAs (shRNAs) that target regions of the <italic toggle="yes">U2AF1</italic> transcripts distant from the S34F missense mutation. The same shRNAs were also introduced in WT1 cells as a control. Allele-sensitive RT-qPCR confirmed that the mRNA ratio of the mutant and wild-type <italic toggle="yes">U2AF1</italic> remained constant (Supplemental Fig. S7A), while the overall U2AF1 mRNA and protein levels were reduced by more than 90% (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-1" hwp:rel-id="F3">Figs. 3A</xref>, bottom panel, and S7B). Knockdown of total <italic toggle="yes">U2AF1</italic> in both MUT1a and WT1 cells did not cause significant changes in recognition of the <italic toggle="yes">ASUN</italic> or <italic toggle="yes">STRAP</italic> cassette exons, two splicing events that are strongly associated with <italic toggle="yes">U2AF1S34F</italic>, in either cell line (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-2" hwp:rel-id="F3">Fig. 3A</xref>, upper panels). Similar results were obtained for two additional S34F-associated cassette exons in <italic toggle="yes">USP25</italic> and <italic toggle="yes">AXL</italic> that exhibit increased inclusion in cells expressing <italic toggle="yes">U2AF1S34F</italic> (Supplemental Fig. S7C, D).</p><fig id="fig3" position="float" fig-type="figure" orientation="portrait" hwp:id="F3" hwp:rev-id="xref-fig-3-1 xref-fig-3-2 xref-fig-3-3 xref-fig-3-4 xref-fig-3-5 xref-fig-3-6 xref-fig-3-7 xref-fig-3-8 xref-fig-3-9 xref-fig-3-10"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;048553v4/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>Fig. 3.</label><caption hwp:id="caption-3"><p hwp:id="p-20"><bold>The ratio of S34F:WT U2AF1 gene products controls S34F-associated splicing in isogenic HBEC3kt cell lines</bold>. (A). Reduction of both mutant and wild-type U2AF1 RNA and protein does not affect S34F-associated splicing. WT1 and MUT1a cells were transduced with shRNAs against <italic toggle="yes">U2AF1</italic> (shU2AF1#1 and #4) or two control shRNAs. Total RNA and protein were harvested 4 days later. The frequencies of incorporation of cassette exon sequences in <italic toggle="yes">ASUN</italic> and <italic toggle="yes">STRAP</italic> mRNAs (top and middle panels) were determined by the relative short/long isoform ratios by RT-qPCR, as represented in <xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-7" hwp:rel-id="F2">Fig. 2C</xref>. Immunoblots for U2AF1 and ACTB in total cell lysates are shown in the bottom panel. shScbr, scrambled shRNA; shGFP, shRNA against GFP. (B). Overexpression of wild-type or mutant U2AF1 to change S34F:WT ratios alters S34F-sensitive splicing. WT1 and MUT1a cells were transduced with expression vectors encoding <italic toggle="yes">GFP</italic>, wild-type (WT) or mutant (S34F) <italic toggle="yes">U2AF1</italic> for 3 days before harvesting cells to quantify the level of splicing changes and proteins as in panel A. (C). Disruption of WT <italic toggle="yes">U2AF1</italic> by gene editing to increase S34F:WT ratios enhances S34F-sensitive splicing. WT1 and MUT1a cells were transduced with either sgRNA-GFP/Cas9 or sgRNA-WT/Cas9. Total RNA and protein were harvested 6 days later for assays as in panel A.</p></caption><graphic xlink:href="048553_fig3" position="float" orientation="portrait" hwp:id="graphic-3"/></fig><p hwp:id="p-21">We next confirmed that knockdown of <italic toggle="yes">U2AF1</italic> was sufficient to alter splicing events known to be dependent on wild-type U2AF1. We studied a competing 3' splice site event in <italic toggle="yes">SLC35C2</italic>, in which the use of an intron-proximal over an intron-distal 3' splice site depends on the level of U2AF1 independent of a <italic toggle="yes">U2AF1</italic> mutation (<xref rid="c16" ref-type="bibr" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">Kralovicova and Vorechovsky 2010</xref>). Knockdown of total <italic toggle="yes">U2AF1</italic> in either WT1 or MUT1a cell lines reduced the use of the U2AF1-dependent intron-proximal 3' splice site (Supplemental Fig. S7E, F). Thus, reduction of <italic toggle="yes">U2AF1</italic> to levels sufficient to affect U2AF1-dependent alternative splicing did not affect S34F-associated splicing in MUT1a cells, when the S34F:WT ratio was maintained.</p><p hwp:id="p-22">We next altered the S34F:WT ratio by separately overexpressing mutant or wild-type <italic toggle="yes">U2AF1</italic> in WT1 and MUT1a cells and examining the subsequent changes in the recognition of the <italic toggle="yes">ASUN</italic> and <italic toggle="yes">STRAP</italic> cassette exons. These cassette exons are preferentially excluded in cells expressing <italic toggle="yes">U2AF1S34F</italic>. Increasing the amount of U2AF1S34F proteinâhence increasing the S34F:WT ratio in either cell typeâfurther enhanced skipping of these cassette exons (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-3" hwp:rel-id="F3">Fig. 3B</xref>). Conversely, decreasing the S34F:WT ratio in MUT1a cells by increasing the production of wild-type U2AF1 protein reduced the extent of exon skipping to approximately the same levels seen in WT1 cells (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-4" hwp:rel-id="F3">Fig. 3B</xref>).</p><p hwp:id="p-23">We also altered the production of wild-type U2AF1 mRNA and protein in MUT1a cells by disrupting the endogenous wild-type <italic toggle="yes">U2AF1</italic> locus with the CRISPR-Cas9 system. Single-guide RNAs (sgRNAs) designed to match either the WT or mutant <italic toggle="yes">U2AF1</italic> sequences were shown to disrupt either reading frame selectively, generating indels (insertions and deletions) at the <italic toggle="yes">U2AF1</italic> locus and thereby changing the S34F:WT ratios (Supplemental Figs. S8, S9). Since WT <italic toggle="yes">U2AF1</italic> is required for the growth of these cells (as shown below; <xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-1" hwp:rel-id="F6">Fig. 6</xref>), we extracted RNA and protein from cells six days after transduction with sgRNA-WT/Cas9, when depletion of wild-type U2AF1 was incomplete (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-5" hwp:rel-id="F3">Fig. 3C</xref>). Selective disruption of wild-type <italic toggle="yes">U2AF1</italic> increased the S34F:WT mRNA ratio in MUT1a cells; as predicted, the extent of exon skipping was further increased in <italic toggle="yes">ASUN</italic> and <italic toggle="yes">STRAP</italic> mRNAs (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-6" hwp:rel-id="F3">Fig. 3C</xref>). Notably, the degree of exon skipping induced by mutant cDNA was similar to that caused by disrupting the wild-type <italic toggle="yes">U2AF1</italic> allele (compare <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-7" hwp:rel-id="F3">Figs. 3C</xref> with <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-8" hwp:rel-id="F3">3B</xref>), even though the absolute protein levels of U2AF1S34F were different in the two experiments. These results show that wild-type U2AF1 antagonizes the activity of U2AF1S34F by a competitive mechanism, such that the S34F:WT ratio controls the magnitude of S34F-associated splicing changes independent of levels of either mutant or wild-type protein.</p></sec><sec id="s2d" hwp:id="sec-6"><title hwp:id="title-8">Disruption of WT U2AF1 globally enhances S34F-associated splicing</title><p hwp:id="p-24">Results in the preceding sections are based on studies of a few well-documented S34F-responsive cassette exons that likely serve as surrogates for the global effects of U2AF1S34F on splice site recognition. To determine whether these results reflect general rules governing S34F-associated splicing, we used RNA-seq to measure the consequences of altering S34F:WT ratios on global recognition of cassette exons. When wild-type <italic toggle="yes">U2AF1</italic> was diminished by CRISPR/Cas9-mediated disruption in MUT1a cells (see <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-9" hwp:rel-id="F3">Fig. 3C</xref>), the S34F-associated changes in inclusion (<xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-1" hwp:rel-id="F4">Fig. 4A</xref>) or exclusion (<xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-2" hwp:rel-id="F4">Fig. 4B</xref>) of cassette exons were enhanced. These global effects are consistent with our measurements of individual cassette exons by RT-qPCR (<xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-10" hwp:rel-id="F3">Fig. 3C</xref>). We also observed a modest increase in the preference for C versus T at the â3 position of the consensus 3' splice sites of cassette exons that were promoted versus repressed in association with <italic toggle="yes">U2AF1S34F</italic> (<xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-3" hwp:rel-id="F4">Fig. 4C</xref>), consistent with the observed association between the S34F:WT mRNA ratio and typical S34F-associated consensus 3' splice sites identified in LUAD tumor transcriptomes (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-8" hwp:rel-id="F1">Fig. 1</xref>).</p><fig id="fig4" position="float" fig-type="figure" orientation="portrait" hwp:id="F4" hwp:rev-id="xref-fig-4-1 xref-fig-4-2 xref-fig-4-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;048553v4/FIG4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F4</object-id><object-id pub-id-type="publisher-id">fig4</object-id><label>Fig. 4.</label><caption hwp:id="caption-4"><p hwp:id="p-25"><bold>Increasing the ratio of S34F:WT gene products by disrupting the wild-type <italic toggle="yes">U2AF1</italic> locus enhances S34F-associated splicing of cassette exons</bold>. (A). Upper panel: The Venn diagrams show overlap of 290 cassette exons that display at least a ten percent increase in inclusion levels in MUT1a cells relative to levels in WT1 cells, with or without CRISPR/Cas9-mediated disruption of wild-type <italic toggle="yes">U2AF1</italic>. Lower panel: Increasing the S34F:WT ratio by disrupting wild-type <italic toggle="yes">U2AF1</italic> enhances the magnitude of S34F-associated splicing. The âwaterfallâ plot depicts changes in percent inclusion levels for all shared cassette exons identified from the Venn diagram when the wild-type <italic toggle="yes">U2AF1</italic> locus was disrupted. Each vertical bar represents one shared cassette exon. (B). The analysis shown in Panel A was repeated for cassette exons showing ten percent or more decreased inclusion in MUT1a cells. (C). Enhanced features of S34F-associated logos at 3â splice acceptor sites after disruption of wild-type <italic toggle="yes">U2AF1</italic>. Sequence logos were constructed as in <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-9" hwp:rel-id="F1">Fig. 1A</xref>, based on the indicated comparisons.</p></caption><graphic xlink:href="048553_fig4" position="float" orientation="portrait" hwp:id="graphic-4"/></fig><p hwp:id="p-26">We observed similar results when we extended our analyses to include other types of alternative splicing beyond cassette exon recognition (Supplemental Fig. S10). We used RT-qPCR to validate five splicing alterations that are sensitive to ablation of wild-type <italic toggle="yes">U2AF1</italic> in the presence of <italic toggle="yes">U2AF1S34F</italic> (Supplemental Fig. S11). Two of the five events involve incorporation of cassette exons (in <italic toggle="yes">ATR</italic> and <italic toggle="yes">MED15</italic>), two involve competition 3' splice sites (in <italic toggle="yes">CASP8</italic> and <italic toggle="yes">SRP19</italic>), and one involves a choice between two mutually exclusive exons (in <italic toggle="yes">H2AFY</italic>). We conclude that the importance of the S34F:WT ratio for S34F-dependent splicing changes extends from cassette exon recognition to other types of alternative splicing.</p></sec><sec id="s2e" hwp:id="sec-7"><title hwp:id="title-9">Changes in RNA splicing correlate with relative binding affinities of mutant and
WT U2AF1 complexes</title><p hwp:id="p-27">Based on the role of U2AF1 in 3' splice site recognition, we hypothesized that differential RNA binding by mutant and WT U2AF1 could contribute to the observed dependence of S34F-associated splicing on the WT:S34F ratios. It has previously been shown that the S34F mutation reduces the binding affinity of the U2AF1-containing complex for a representative skipped splice site (<xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-4" hwp:rel-id="ref-23">Okeyo-Owuor et al. 2015</xref>). However, whether changes in RNA binding could account for exon inclusion, as well as the generality of this observation, were unknown. We therefore tested whether altered RNA-binding affinity explained mutation-dependent increases (<italic toggle="yes">ZFAND1, FXR1, ATR, MED15</italic>) and decreases (<italic toggle="yes">CEP164</italic>) in exon inclusion, as well as competing 3' splice site recognition (<italic toggle="yes">FMR1</italic>). These splicing events exhibited S34F-associated alterations in both our isogenic cell lines (Supplemental Table S1) and in LUAD transcriptomes (Supplemental Table S2).</p><p hwp:id="p-28">We determined the RNA binding affinities of purified U2AF1-containing protein complexes using fluorescence anisotropy assays, in which the anisotropy increases of fluorescein-labeled RNA oligonucleotides following protein titration were fit to obtain the apparent equilibrium binding affinities (Supplemental Fig. S12; Supplemental Materials and Methods). The recombinant proteins comprised either WT or S34F-mutant U2AF1 as ternary complexes with the U2AF2 and SF1 subunits that recognize the adjoining 3' splice site consensus sequences. The constructs were nearly full length and included the relevant domains for 3' splice site recognition (<xref rid="c32" ref-type="bibr" hwp:id="xref-ref-32-2" hwp:rel-id="ref-32">Wu et al. 1999</xref>; <xref rid="c19" ref-type="bibr" hwp:id="xref-ref-19-1" hwp:rel-id="ref-19">Liu et al. 2001</xref>; <xref rid="c1" ref-type="bibr" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">Agrawal et al. 2016</xref>) (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-1" hwp:rel-id="F5">Fig. 5A</xref>). The six pairs of tested RNA oligonucleotides (33 - 35 nucleotides in length) were derived from the proximal or distal 3' splice sites of the six genes listed above (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-2" hwp:rel-id="F5">Figs. 5B</xref>, S12). Combined with prior results for sequence variants derived from the S34F-skipped <italic toggle="yes">DEK</italic> cassette exon (<xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-5" hwp:rel-id="ref-23">Okeyo-Owuor et al. 2015</xref>), we have in total measured binding affinities for 16 RNA oligonucleotides, which consist of five sequences with a U at the â3 position of the 3' splice site (âUAGâ splice sites), seven âCAGâ splice sites, and four âAAGâ splice sites.</p><fig id="fig5" position="float" fig-type="figure" orientation="portrait" hwp:id="F5" hwp:rev-id="xref-fig-5-1 xref-fig-5-2 xref-fig-5-3 xref-fig-5-4 xref-fig-5-5 xref-fig-5-6 xref-fig-5-7 xref-fig-5-8 xref-fig-5-9 xref-fig-5-10 xref-fig-5-11 xref-fig-5-12 xref-fig-5-13 xref-fig-5-14 xref-fig-5-15 xref-fig-5-16"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;048553v4/FIG5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F5</object-id><object-id pub-id-type="publisher-id">fig5</object-id><label>Fig. 5.</label><caption hwp:id="caption-5"><p hwp:id="p-29"><bold>Differential binding of mutant and wild-type U2AF1 complexes to RNA oligonucleotides explains most S34F-associated alterations in RNA splicing</bold>. (A). Cartoons illustrate components of recombinant U2AF1 complexes used in the binding assay. Full-length proteins are shown but only partial sequences (denoted by bidirectional arrows) were used to make recombinant protein complexes. KH-QUA2, K-Homology Quaking motif; RRM, RNA recognition motif domain; RS, arginine/serine-rich domain; UHM, U2AF homology motif; ULM, U2AF ligand motif; ZnF, zinc finger domain. (B). Scheme of alternative splicing patterns for cassette exons (top diagram) and 5' extended exons from competing 3' splice site selection (bottom). The brackets indicate the positions of RNA oligonucleotides used for the binding assays. Exons are shown as boxes: white boxes indicate invariant exonic sequences and black boxes denote sequences that are incorporated into mRNA (exonic) only when the proximal 3â splice sites are used. Introns are shown as solid lines. The grey lines represent possible splices. The names of characterized genes that conform to the patterns shown in the upper and lower cartoons are indicated. (C - H). Mutant and wild-type U2AF1 complexes have different affinities (K<sub>A</sub>'s) for relevant 3â splice site oligonucleotides. To accomplish the binding assays, the wild-type or mutant U2AF1 protein complexes were titrated into 5' fluorescein-tagged RNA oligonucleotides over a range of concentrations as described in the Supplemental Materials and Methods. RNA sequences from â4 to +3 relative to the 3' splice sites (vertical lines) in proximal and distal positions are shown. The nucleotide at the â3 position is bolded and underlined. Empty bars, K<sub>A</sub> for WT U2AF1 complex; grey bar, K<sub>A</sub> for mutant U2AF1 complex. For ease of comparison between the affinity binding results with S34F-associated splicing, S34F-promoted splices, as determined from RNA-seq data, are shown on top of each bar graph in black lines. The fitted binding curves, full oligonucleotide sequences, and apparent equilibrium dissociation constants are shown in Supplemental Fig. S12. The relative changes in affinity and use of proximal <italic toggle="yes">versus</italic> distal splice sites are summarized in Supplemental Table S3. The asterisk represents a statistically significant change by unpaired t-tests with Welch's correction (p value &lt; 0.05). ns, not significant, p value &gt; 0.05.</p></caption><graphic xlink:href="048553_fig5" position="float" orientation="portrait" hwp:id="graphic-5"/></fig><p hwp:id="p-30">The trends among S34F-altered RNA binding affinities of U2AF1 complexes (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-3" hwp:rel-id="F5">Fig. 5C â H</xref>) for the tested splice site sequences generally agreed with the nucleotide distributions observed in consensus 3' splice site that are promoted or repressed by <italic toggle="yes">U2AF1S34F</italic> (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-10" hwp:rel-id="F1">Figs. 1A</xref>, S1A). The S34F mutation reduced the affinities of U2AF1-containing complexes for four out of five tested âUAGâ splice sites, consistent with T as the most common nucleotide at the â3 position of the 3' splice site (henceforth referred to as â3T) for S34F-repressed exons. Likewise, the S34F mutation often increased the affinities of U2AF1 complexes for âCAGâ splice sites (for three out of seven tested sequences), consistent with â3C as the most common nucleotide preceding S34F-promoted exons. The remaining tested âUAGâ or âCAGâ splice sites showed no significant difference between S34F and WT protein binding. The âAAGâ splice sites lacked a consistent relationship to the S34F-induced RNA affinity changes of U2AF1 complexes <italic toggle="yes">per se</italic>. However, the S34F mutation increased the binding of the U2AF1-containing complex for one âAAGâ splice site for an S34F-promoted exon (<italic toggle="yes">ZFAND1</italic>), which is consistent with the greater prevalence of â3A than â3T preceding S34F-promoted exons.</p><p hwp:id="p-31">Overall, the altered binding affinities of U2AF1-containing complexes for the proximal 3' splice site could account for four of the six S34F-associated alternative splicing events (<italic toggle="yes">CEP164, FMR1, ZFAND1, FXR1</italic>) (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-4" hwp:rel-id="F5">Figs. 5C â 5F</xref>, Supplementary Table S3). Similar to the previously-tested S34F-skipped splice site in <italic toggle="yes">DEK</italic> (<xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-6" hwp:rel-id="ref-23">Okeyo-Owuor et al. 2015</xref>), the S34F mutation decreased affinities of the U2AF1-containing complexes for the skipped 3' splice sites of the <italic toggle="yes">CEP164</italic> and <italic toggle="yes">FMR1</italic> exons (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-5" hwp:rel-id="F5">Fig. 5C â D</xref>). Remarkably, the S34F mutation enhanced binding of the U2AF1-containing complexes to the proximal 3' splice sites of <italic toggle="yes">ZFAND1</italic> and <italic toggle="yes">FXR1</italic> (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-6" hwp:rel-id="F5">Fig. 5E â F</xref>), which could explain the enhanced inclusion of these exons in cell lines and LUAD (Supplementary Table S3). In agreement with the observed splicing changes, the S34F mutation had no significant effect on the distal 3' splice sites of these exons.</p><p hwp:id="p-32">The affinities of the mutant U2AF1 complexes for the proximal splice site oligonucleotides of the remaining two S34F-promoted exons (<italic toggle="yes">ATR</italic> and <italic toggle="yes">MED15</italic>) were either similar to wild-type or decreased (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-7" hwp:rel-id="F5">Fig. 5G</xref>, <xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-8" hwp:rel-id="F5">H</xref>). These results differed from the S34F-dependent increase in U2AF1 binding to the proximal 3' splice site that was observed for <italic toggle="yes">ZFAND1</italic> and <italic toggle="yes">FXR1</italic> (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-9" hwp:rel-id="F5">Fig. 5E</xref>, <xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-10" hwp:rel-id="F5">F</xref>), which could readily explain the enhanced exon inclusions. However, for the <italic toggle="yes">ATR</italic> pre-mRNA, the <italic toggle="yes">U2AF1</italic> mutation reduced binding to the distal more than to the proximal 3' splice site (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-11" hwp:rel-id="F5">Fig. 5G</xref>, third and fourth columns). Given co-transcriptional splicing in the 5'-toâ3' direction, the downstream (as opposed to upstream) 3' splice sites could compete as splicing acceptors for a given 5' donor splice site when transcription is relatively rapid as compared to splicing. (Such 3' splice site competition likely occurs relatively frequently, as the <italic toggle="yes">ATR</italic> cassette exon is alternatively spliced even in wild-type cells). As such, a ânet gainâ in affinity for the proximal relative to distal 3' splice site could explain the observed S34F-associated exon inclusion in <italic toggle="yes">ATR</italic> mRNAs. For the <italic toggle="yes">MED15</italic> pre-mRNA, deviation of the S34F-associated splicing changes and a simple RNA affinity model suggested that additional mechanisms control selection of the <italic toggle="yes">MED15</italic> 3' splice sites. In total, our measurements of <italic toggle="yes">in vitro</italic> RNA-binding affinities are sufficient to explain six of seven tested alterations in splice site recognition driven by <italic toggle="yes">U2AF1S34F</italic> (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-12" hwp:rel-id="F5">Fig 5C</xref>â<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-13" hwp:rel-id="F5">H</xref> and in <xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-7" hwp:rel-id="ref-23">Okeyo-Owuor et al. 2015</xref>).</p></sec><sec id="s2f" hwp:id="sec-8"><title hwp:id="title-10">HBEC3kt and LUAD cells are not dependent on <italic toggle="yes">U2AF1S34F</italic> for growth, but wild-type <italic toggle="yes">U2AF1</italic> is absolutely required</title><p hwp:id="p-33">Other than its effect on RNA splicing, the consequences of the <italic toggle="yes">U2AF1S34F</italic> mutation on cell behavior are largely unknown. Recurrent mutations, such as <italic toggle="yes">U2AF1 S34F</italic>, are considered likely to confer a selective advantage to cells in which they occur when expressed at physiologically relevant levels. However, mutant HBEC3kts cells (MUT1a and MUT1b) do not exhibit obvious phenotypic properties of neoplastic transformationâsuch as a growth advantage over wild-type cells (Supplemental Fig. S13) or an ability to grow in an anchorage-independent mannerâthat are frequently observed in cultured cells expressing well-known oncogenes, like mutant <italic toggle="yes">RAS</italic> genes.</p><p hwp:id="p-34">Another attribute of some well-known oncogenes, such as <italic toggle="yes">BCR-ABL</italic> fusion in chronic myeloid leukemia or mutant <italic toggle="yes">EGFR</italic> or <italic toggle="yes">KRAS</italic> in LUAD, is the dependence on sustained expression of those oncogenes for the maintenance of cell growth or viability. To determine whether LUAD cells harboring a pre-existing S34F mutation are dependent upon (or âaddicted toâ) the mutant allele, we searched the COSMIC database for LUAD cell lines with the <italic toggle="yes">U2AF1S34F</italic> allele (<xref rid="c11" ref-type="bibr" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">Forbes et al. 2015</xref>). We found two such lines (H441 and HCC78) and confirmed the retention of the <italic toggle="yes">U2AF1S34F</italic> allele by Sanger sequencing and allele-specific RT-qPCR (Supplemental Fig. S14A). We used the CRISPR-Cas9 system to selectively disrupt the wild-type or mutant <italic toggle="yes">U2AF1</italic> sequences. We then assessed the impact of inactivating the <italic toggle="yes">U2AF1</italic> alleles on the clonogenic growth of the two LUAD lines with the <italic toggle="yes">U2AF1</italic> mutation. In addition, we performed similar experiments with the LUAD cell line A549 (wild-type for U2AF1) and the HBEC3kt-derived MUT1a cell line.</p><p hwp:id="p-35">In all instances, loss of the mutant allele did not impair cell growth. Only one line (H441) exhibited altered growth, in the form of a two-fold increase in clonogenicity (<xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-2" hwp:rel-id="F6">Fig. 6A</xref>). Successful disruption of the <italic toggle="yes">U2AF1S3F</italic> allele was confirmed by restoration of a normal RNA splicing profile in subclonal cells derived from the clonogenic assay colonies (see Supplemental Figs. S14 - S17, Tables S4 and S5, and text below). In contrast, loss of the wild-type allele completely inhibited clonogenic growth in all tested cell lines, regardless of whether the line carried the <italic toggle="yes">U2AF1S34F</italic> allele or not. A rescue experiment confirmed that loss of cell growth was due to loss of wild-type <italic toggle="yes">U2AF1</italic> expression. The loss of clonogenic capacity after disrupting endogenous <italic toggle="yes">U2AF1</italic> in A549 cells was prevented by first transducing them with a form of wild-type <italic toggle="yes">U2AF1</italic> cDNA (<xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-3" hwp:rel-id="F6">Fig. 6B</xref>) that is not predicted to be a target for sgRNA-WT/Cas9 (Supplemental Fig. S8). Overall, these findings indicate that wild-type <italic toggle="yes">U2AF1</italic> is required for the clonogenic growth of cells, including lung cancer cell lines, that the S34F mutant is unable to compensate for loss of the wild-type allele, and that LUAD cells with the S34F mutation are not dependent on the mutant allele for growth <italic toggle="yes">in vitro</italic>.</p><fig id="fig6" position="float" fig-type="figure" orientation="portrait" hwp:id="F6" hwp:rev-id="xref-fig-6-1 xref-fig-6-2 xref-fig-6-3 xref-fig-6-4 xref-fig-6-5 xref-fig-6-6 xref-fig-6-7"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;048553v4/FIG6</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F6</object-id><object-id pub-id-type="publisher-id">fig6</object-id><label>Fig. 6.</label><caption hwp:id="caption-6"><p hwp:id="p-36"><bold>Wild-type but not mutant <italic toggle="yes">U2AF1</italic> is required for the clonogenic growth of the isogenic HBEC3kt cells and LUAD cell lines</bold>. (A). Clonogenic growth assays after selective disruption of the wild-type or mutant <italic toggle="yes">U2AF1</italic> allele. Left panel: The indicated cell lines were transduced with lentiviruses expressing sgRNA-GFP/Cas9, sgRNA-S34F/Cas9 or sgRNA-WT/Cas9, followed by clonogenic assays. Cell colonies were stained with methylene blue and counted three weeks later. Right panel: Quantification of the clonogenic assay. The results are shown as percent clonogenicity by setting the number of control cell colonies (cells treated with Cas9/sgRNA-GFP) as 100% (n = 3). (B). Rescue of growth inhibition by sgRNA-WT/Cas9 by overexpressing a form of wild-type <italic toggle="yes">U2AF1</italic> cDNA that is not predicted to be the target for sgRNA-WT/Cas9 (See Supplemental Fig. S8 and Materials and Methods). Left panel: A549 cells were transduced with a control (DsRed-Express 2) or a wild-type <italic toggle="yes">U2AF1</italic> cDNA that is not predicted to be the target for sgRNA-WT/Cas9. Increased expression of wild-type U2AF1 was confirmed by immunoblot (left bottom panel).
These cells were subsequently transduced with either sgRNA-GFP/Cas9 or sgRNA-WT/Cas9 followed by clonogenic assays as in panel A (left upper panel). Right panel: Quantification as in Panel A (n = 3).</p></caption><graphic xlink:href="048553_fig6" position="float" orientation="portrait" hwp:id="graphic-6"/></fig><p hwp:id="p-37">To examine the effect of <italic toggle="yes">U2AF1S34F</italic> on tumor growth <italic toggle="yes">in vivo</italic>, we derived H441 and HCC78 cells transduced with sgRNA-S34F/Cas9 or sgRNA-GFP/Cas9 as polyclonal pools or as clones (Supplemental Figs. S14, S15). The cell lines were verified to either carry or not carry the <italic toggle="yes">U2AF1S34F</italic> allele, and we confirmed that the sgRNA-S34F/Cas9-transduced cells lost the S34F-associated splicing program (Supplemental Figs. S16, S17).</p><p hwp:id="p-38">We inoculated these subclonal cell lines subcutaneously in nude mice and monitored xenograft tumor growth. The H441-derived cell lines, in which the <italic toggle="yes">U2AF1S34F</italic> allele was disrupted, were able to establish tumors <italic toggle="yes">in vivo</italic> at rates similar to those observed for tumor cells carrying the mutant allele (Supplemental Table S6). The HCC78-derived cell lines did not grow palpable tumors after xenografting within the observation period, so the requirement for <italic toggle="yes">U2AF1S34F in vivo</italic> could not be tested in that line. These experiments show that <italic toggle="yes">U2AF1S34F</italic> is dispensable for growth of these LUAD cell lines <italic toggle="yes">in vivo</italic>, a result consistent with the clonogenicity assays shown in <xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-4" hwp:rel-id="F6">Fig. 6</xref>. We conclude that <italic toggle="yes">U2AF1S34F</italic> appears to be neither sufficient nor necessary for lung cell transformation in these assays. In contrast, wild-type <italic toggle="yes">U2AF1</italic> is required for cell viability, consistent with the retention of a wild-type allele in human cancers carrying common <italic toggle="yes">U2AF1</italic> mutations.</p></sec></sec><sec id="s3" hwp:id="sec-9"><title hwp:id="title-11">Discussion</title><p hwp:id="p-39">In this report, we have examined the mechanistic and phenotypic consequences of the common <italic toggle="yes">U2AF1S34F</italic> mutation. Our data demonstrate that the S34F:WT ratio controls the quantitative consequences of the <italic toggle="yes">U2AF1</italic> mutation for splice site recognition, and suggest that differential RNA-binding affinities of the mutant and wild-type protein result in preferential recognition of specific 3' splice sites. Moreover, our finding that wild-type <italic toggle="yes">U2AF1</italic> is required for cell survival irrespective of the presence or absence of <italic toggle="yes">U2AF1S34F</italic> explains the genetic observation that tumors always retain an expressed copy of the wild-type allele. Finally, we expect that the genetic models of <italic toggle="yes">U2AF1S34F</italic> that we derived from immortalized lung epithelial cells, as well as cell lines derived from lung adenocarcinomas with the mutation, will prove useful for future functional studies of this common mutation.</p><sec id="s3a" hwp:id="sec-10"><title hwp:id="title-12">The S34F:WT ratio controls S34F-associated splicing</title><p hwp:id="p-40">U2AF1S34F is known to induce specific splicing alterations, but it is not known how these changes are regulated. We show that the ratio of S34F:WT U2AF1 gene products is a critical determinant of the magnitude of S34F-associated splicing. This conclusion was demonstrated in an isogenic lung epithelial cell line engineered to express <italic toggle="yes">U2AF1S34F</italic> from one of the two endogenous <italic toggle="yes">U2AF1</italic> loci, and was further supported by analyses of human LUAD transcriptomes carrying the <italic toggle="yes">U2AF1S34F</italic> allele. These results suggest that wild-type U2AF1 antagonizes the splicing program associated with the S34F mutation.</p></sec><sec id="s3b" hwp:id="sec-11"><title hwp:id="title-13">Altered RNA binding affinities often explain S34F-associated splicing changes</title><p hwp:id="p-41">We find that a major functional difference between purified S34F mutant and wild-type U2AF1 proteins resides in altered binding affinities for a subset of 3' splice sites. The trends in the RNA sequence preferences of S34F-mutant U2AF1 are consistent with the preferred 3' splice sites of S34F-affected transcripts (here and in (<xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-5" hwp:rel-id="ref-14">Ilagan et al. 2015</xref>; <xref rid="c4" ref-type="bibr" hwp:id="xref-ref-4-5" hwp:rel-id="ref-4">Brooks et al. 2014</xref>; <xref rid="c25" ref-type="bibr" hwp:id="xref-ref-25-4" hwp:rel-id="ref-25">Przychodzen et al. 2013</xref>; <xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-8" hwp:rel-id="ref-23">Okeyo-Owuor et al. 2015</xref>; <xref rid="c29" ref-type="bibr" hwp:id="xref-ref-29-1" hwp:rel-id="ref-29">Shirai et al. 2015</xref>)), which we use as the signature of S34F-associated differential splicing (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-11" hwp:rel-id="F1">Fig. 1A</xref>). For oligonucleotides that showed significant changes in binding affinities, the S34F mutation typically reduced or enhanced respective binding of the U2AF1 splicing factor complexes to 3' splice sites preceded by a â3U or â3C (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-14" hwp:rel-id="F5">Fig. 5</xref> and (<xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-9" hwp:rel-id="ref-23">Okeyo-Owuor et al. 2015</xref>)). In support of our findings for the relevant ternary complex of human U2AF1, U2AF2 and SF1 subunits, recent studies confirmed that the corresponding S34F mutation inhibited binding of the minimal fission yeast U2AF heterodimer to a âUAGâ splice site RNA (<xref rid="c33" ref-type="bibr" hwp:id="xref-ref-33-2" hwp:rel-id="ref-33">Yoshida et al. 2015</xref>). These S34F-altered RNA affinities are consistent with the location of the substituted amino acid in a zinc knuckle that may directly contact RNA (<xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-6" hwp:rel-id="ref-14">Ilagan et al. 2015</xref>). Although the effects of the S34F mutation on binding 3' splice sites preceded by â3A are variable, extrusion or alternative U2AF1 binding sites for disfavored nucleotides could occur in different sequence contexts by analogy with other RNA binding proteins (Lu and <xref rid="c20" ref-type="bibr" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">Hall 2011</xref>; <xref rid="c22" ref-type="bibr" hwp:id="xref-ref-22-1" hwp:rel-id="ref-22">Miller et al. 2008</xref>).</p><p hwp:id="p-42">Several lines of evidence support the idea that U2AF1S34F is capable of initiating pre-mRNA splicing once it binds to RNA. Nuclear extracts of cells overexpressing mutant <italic toggle="yes">U2AF1</italic> can support <italic toggle="yes">in vitro</italic> splicing reactions more efficiently than nuclear extracts derived from cells overexpressing wild-type <italic toggle="yes">U2AF1</italic> for a minigene with specific 3' splice site sequence (<xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-7" hwp:rel-id="ref-14">Ilagan et al. 2015</xref>). In addition, mutant U2AF1 can compensate for the loss of wild-type factor for the inclusion of some U2AF1-dependent cassette exons (<xref rid="c28" ref-type="bibr" hwp:id="xref-ref-28-1" hwp:rel-id="ref-28">Shao et al. 2014</xref>). Our observations that the altered RNA-binding affinities correlate well with S34F-associated splicing for the majority of splice sites that we tested further suggest that mutant and wild-type U2AF1 are functionally equivalent for downstream steps of splicing (<xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-15" hwp:rel-id="F5">Fig. 5</xref> and in <xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-10" hwp:rel-id="ref-23">Okeyo-Owuor et al. 2015</xref>).</p></sec><sec id="s3c" hwp:id="sec-12"><title hwp:id="title-14">A working model of S34F-associated Splicing</title><p hwp:id="p-43">In light of our findings and existing evidence from the literature, we propose a model wherein mutant U2AF1 drives differential splicing by favoring the recognition of one of two competing 3' splice sites. This model is motivated by three key facts. First, alternative splicing, in contrast to constitutive splicing, necessarily results from implicit or explicit competition between splice sites. (For example, cassette exon recognition involves competition between the 3' splice sites of the cassette exon itself and a downstream constitutive exon.) Second, mutant and wild-type U2AF1 complexes have different binding specificities, largely due to their preferences for distinct nucleotides at the â3 position, that lead them to preferentially bind distinct 3' splice sites. Third, mutant and wild-type U2AF1 are likely functionally equivalent once they bind to RNA.</p><p hwp:id="p-44">Therefore, altering the cellular ratio of mutant and wild-type U2AF1 changes the amount of total U2AF1 bound to a given 3' splice site in a sequence-specific manner, thereby promoting or repressing that splice site relative to a competing 3' splice site.</p><p hwp:id="p-45">Our proposed model is not exclusive of other possible contributing effects, such as competitive binding of mutant and wild-type U2AF1 to a factor with low stoichiometry, or effects of U2AF1S34F on the kinetics of co-transcriptional splicing as suggested recently (<xref rid="c8" ref-type="bibr" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">Coulon et al. 2014</xref>). Future studies are needed to resolve these possibilities.</p></sec><sec id="s3d" hwp:id="sec-13"><title hwp:id="title-15">How are cells with the U2AF1 S34F mutation selected during oncogenesis?</title><p hwp:id="p-46"><italic toggle="yes">U2AF1S34F</italic> is recurrently found in LUAD, other solid tumors, and myeloid disorders, suggesting that the mutant allele confers a physiological property that provides a selective advantage during neoplasia. However, we did not observe signs of neoplastic transformation or changes in cell proliferation after introducing <italic toggle="yes">U2AF1S34F</italic> into the endogenous <italic toggle="yes">U2AF1</italic> locus in HBEC3kt cells (Supplemental Fig. S13; data not shown). Moreover, targeted inactivation of <italic toggle="yes">U2AF1S34F</italic> in LUAD cell lines does not diminish, and in one case even increases, clonogenic growth in culture (<xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-5" hwp:rel-id="F6">Fig. 6</xref>).</p><p hwp:id="p-47">The lack of a testable cellular phenotype has been a major hindrance to understanding the functional significance of mutant <italic toggle="yes">U2AF1</italic> in carcinogenesis. Cell proliferation is only one of the many hallmarks of cancer, so careful examination of other cell properties in the isogenic cells may be needed to establish the presumptive role of <italic toggle="yes">U2AF1S34F</italic> in carcinogenesis.</p><p hwp:id="p-48">Recently, Park et al have reported that tumorigenic cells emerge after U2AF1-S34F is ectopically produced in Ba/F3 pro-B cells or in an immortalized line of small airway epithelial cells (<xref rid="c24" ref-type="bibr" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">Park et al. 2016</xref>). The authors attribute the transformation events by mutant U2AF1 to 3' processing of mRNA's. In particular, they observed an increase in the length of the 3' untranslated region of <italic toggle="yes">ATG7</italic> mRNA and a reduction in ATG7 protein, and propose that the anticipated defect in autophagy predisposes the cells to mutations that cause transformation. This âhit-and-runâ type of mechanism is consistent with our observation and theirs that mutant U2AF1 is dispensable for maintenance of the transformed phenotype in LUAD cell lines (<xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-6" hwp:rel-id="F6">Figure 6</xref>) and in their cell lines (<xref rid="c24" ref-type="bibr" hwp:id="xref-ref-24-2" hwp:rel-id="ref-24">Park et al. 2016</xref>). Their observations do not, moreover, exclude a role for S34F-associated splicing in the oncogenic mechanism.</p></sec><sec id="s3e" hwp:id="sec-14"><title hwp:id="title-16">Can cancer cells carrying the S34F mutation be targeted therapeutically?</title><p hwp:id="p-49">We have shown that the wild-type <italic toggle="yes">U2AF1</italic> allele is absolutely required for the growth of lung epithelial and LUAD cells that carry a mutant <italic toggle="yes">U2AF1</italic> allele (<xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-7" hwp:rel-id="F6">Fig. 6</xref>). This result indicates that mutant U2AF1 cannot complement a deficiency of wild-type U2AF1 and explains why tumors are never homozygous for the <italic toggle="yes">U2AF1S34F</italic> mutation. Furthermore, the frequent occurrence of a low ratio of S34F:WT <italic toggle="yes">U2AF1</italic> mRNA, accompanied by increased copy number of wild-type <italic toggle="yes">U2AF1</italic> alleles, suggests that there may be selection for a lower ratio of S34F:WT in addition to the likely selection, perhaps at an earlier stage of tumorigenesis, for the S34F mutant. These results are consistent with a study of mutations affecting the splicing factor SF3B1, which reported that cancer cells harboring recurrent <italic toggle="yes">SF3B1</italic> mutations also depend on wild-type SF3B1 for growth (<xref rid="c37" ref-type="bibr" hwp:id="xref-ref-37-1" hwp:rel-id="ref-37">Zhou et al. 2015</xref>). Finally, a recent study similarly found that a wild-type copy of <italic toggle="yes">SRSF2</italic> is required for leukemic cell survival, and that <italic toggle="yes">SRSF2</italic> mutations generated a therapeutic index for treatment with a small molecule that inhibits 3' splice site recognition (<xref rid="c18" ref-type="bibr" hwp:id="xref-ref-18-1" hwp:rel-id="ref-18">Lee et al. 2016</xref>). Together, our results and these recent studies provide a genetic rationale for targeting wild-type splicing factors (or the splicing machinery more generally) in cancers harboring spliceosomal mutations.</p></sec></sec><sec id="s4" hwp:id="sec-15"><title hwp:id="title-17">Materials and Methods</title><sec id="s4a" hwp:id="sec-16"><title hwp:id="title-18"><italic toggle="yes">Cell culture, reagents, and assays</italic></title><p hwp:id="p-50">The HBEC3kt cells (a gift from Dr. John Minna, UT Southwestern Medical Center), H441, A549 (ATCC) and HCC78 cells (DMSZ) were cultured as previously described (<xref rid="c26" ref-type="bibr" hwp:id="xref-ref-26-2" hwp:rel-id="ref-26">Ramirez et al. 2004</xref>) or according to vendors' instructions. The primary antibodies for immunoblots are: rabbit anti U2AF1 (1:5000, # NBP1-19121, Novus), rabbit anti GFP (1:5000, #A-11122, Invitrogen), mouse anti ACTB (1:5000, Clone 8H10D10, Cell Signaling). Lentiviruses were produced and titered in HEK293T cells as previously described (<xref rid="c10" ref-type="bibr" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">Fei et al. 2012</xref>). An MOI (multiplicity of infection) of 1 - 5 were used for all assays.</p><p hwp:id="p-51">Total RNA was extracted and reverse transcribed as previously described (<xref rid="c9" ref-type="bibr" hwp:id="xref-ref-9-1" hwp:rel-id="ref-9">Fei et al. 2010</xref>). Splicing alterations were measured by quantitative PCR on reverse-transcribed cDNA (RT-qPCR), using isoform-specific primers (Supplemental Table S7). These primers were designed following a previously described method (<xref rid="c5" ref-type="bibr" hwp:id="xref-ref-5-1" hwp:rel-id="ref-5">Brosseau et al. 2010</xref>). The PCR efficiency and specificity of each primer set were determined before they were used for measuring splicing changes (See Supplemental Materials and Methods for details).</p><p hwp:id="p-52">Clonogenic assay was performed by infecting cells with lentiviruses two days before seeding them into 100 mm dishes (1000 live cells per dish) to grow colonies. Growth media were supplemented with puromycin (1 Î¼lg/ml) for selecting infected cells and were changed once a week for up to three weeks. Cell colonies were stained with 0.03% methylene blue (in 20% methanol) for 5 min. Clonogenicity is defined as colony numbers formed as a percent of those in control cells.</p><p hwp:id="p-53">Details of all DNA constructs used in the study and the genome editing approaches for creating the <italic toggle="yes">U2AF1S34F</italic> allele and allelic-specific disruption of <italic toggle="yes">U2AF1</italic> are described in the Supplemental Materials and Methods.</p></sec><sec id="s4b" hwp:id="sec-17"><title hwp:id="title-19"><italic toggle="yes">mRNA sequencing and analysis</italic></title><p hwp:id="p-54">High throughput mRNA sequencing (RNA-seq) was conducted in the Sequencing Facility of the National Cancer Institute. RNA quality was assessed by 2100 Bioanalyzer (Agilent). Total RNA with good integrity values (RIN &gt; 9.0) was used for poly A selection and library preparation using the Illumina TruSeq RNA library prep kit. Two or four samples were pooled per lane and ran on the HiSeq2000 or HiSeq2500 instrument using TruSeq V3 chemistry. All samples were sequenced to the depth of at least 100 million pair-end 101 bp reads per sample.</p><p hwp:id="p-55">Splicing analysis of RNA-seq data from the TCGA LUAD cohort as well as engineered HBEC3kt, H441, and HCC78 cell lines was performed as previously described (<xref rid="c14" ref-type="bibr" hwp:id="xref-ref-14-8" hwp:rel-id="ref-14">Ilagan et al. 2015</xref>). A brief description of the method was provided in the Supplemental Materials and Methods.</p></sec><sec id="s4c" hwp:id="sec-18"><title hwp:id="title-20"><italic toggle="yes">Purification of U2AF1 protein complexes and RNA affinity measurement</italic></title><p hwp:id="p-56">Purification of U2AF1 complexes, as illustrated in <xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-16" hwp:rel-id="F5">Fig.5</xref>, was explained in Supplemental Materials and Methods. Sequences of synthetic 5'-labeled fluorescein RNAs (GE Healthcare Dharmacon) and binding curves are given in the Supplementary Fig. S12. Apparent equilibrium affinity constant of the purified U2AF1 complexes with RNA was measured based on changes in fluorescence anisotropy as previously described (<xref rid="c23" ref-type="bibr" hwp:id="xref-ref-23-11" hwp:rel-id="ref-23">Okeyo-Owuor et al. 2015</xref>). A brief description of this method was provided in the Supplemental Materials and Methods.</p></sec><sec id="s4d" hwp:id="sec-19"><title hwp:id="title-21"><italic toggle="yes">Statistics</italic></title><p hwp:id="p-57">All experiments were independently performed at least three times unless otherwise stated. Statistical significance was determined by two-tailed Student's <italic toggle="yes">t</italic> test or otherwise stated. In all analyses, <italic toggle="yes">p</italic> values &lt; 0.05 are considered statistically significant.</p></sec></sec></body><back><ack hwp:id="ack-1"><title hwp:id="title-22">Acknowledgements</title><p hwp:id="p-58">We thank Ms. Jackie Idol, Ursula Harper, Danielle Miller-O'Mard and the transgenic mouse core at NHGRI for technical assistance, Dr. Heidi Dvinge (FHCRC) for help with the LUAD data analysis, Dr. Matthew J. Walter (Wash.U.) for sharing the <italic toggle="yes">CEP164</italic> and <italic toggle="yes">FMR1</italic> splice site sequences prior to publication. We thank members of the Varmus lab, Drs. Janine Ilagan (FHCRC) and Paul Liu (NHGRI) for helpful discussions during the course of the study. HV was supported by the Intramural Program at the National Institutes of Health and is now supported by the Meyer Cancer Center at Weill Cornell Medicine. RKB is supported by the Edward P. Evans Foundation, Ellison Medical Foundation (AG-NS-1030-13), NIH/NHLBI (R01 HL128239), and NIH/NIDDK (R01 DK103854). CLK is supported by the Edward P. Evans Foundation and NIH/NIGMS (R01 GM070503). The results published here are in part based upon data generated by the TCGA Research Network: <ext-link l:rel="related" l:ref-type="uri" l:ref="http://cancergenome.nih.gov/" ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/" hwp:id="ext-link-2">http://cancergenome.nih.gov/</ext-link>.</p></ack><ref-list hwp:id="ref-list-1"><title hwp:id="title-23">References</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="Agrawal AA"><surname>Agrawal</surname><given-names>AA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Salsi E"><surname>Salsi</surname><given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chatrikhi R"><surname>Chatrikhi</surname><given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Henderson S"><surname>Henderson</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jenkins JL"><surname>Jenkins</surname><given-names>JL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Green MR"><surname>Green</surname><given-names>MR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ermolenko DN"><surname>Ermolenko</surname><given-names>DN</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kielkopf CL"><surname>Kielkopf</surname><given-names>CL</given-names></string-name>. <year>2016</year>. <article-title hwp:id="article-title-2">An extended U2AF(65)-RNA-binding domain recognizes the 3' splice site signal</article-title>. <source hwp:id="source-1">Nat Commun</source> <volume>7</volume>: <fpage>10950</fpage>.</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Berglund JA"><surname>Berglund</surname><given-names>JA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Abovich N"><surname>Abovich</surname><given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rosbash M"><surname>Rosbash</surname><given-names>M</given-names></string-name>. <year>1998</year>. <article-title hwp:id="article-title-3">A cooperative interaction between U2AF65 and mBBP/SF1 facilitates branchpoint region recognition</article-title>. <source hwp:id="source-2">Genes &amp; Development</source> <volume>12</volume>: <fpage>858</fpage>â<lpage>867</lpage>.</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Biankin AV"><surname>Biankin</surname><given-names>AV</given-names></string-name>, <string-name name-style="western" hwp:sortable="Waddell N"><surname>Waddell</surname><given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kassahn KS"><surname>Kassahn</surname><given-names>KS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gingras M-C"><surname>Gingras</surname><given-names>M-C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Muthuswamy LB"><surname>Muthuswamy</surname><given-names>LB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Johns AL"><surname>Johns</surname><given-names>AL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Miller DK"><surname>Miller</surname><given-names>DK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wilson PJ"><surname>Wilson</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Patch A-M"><surname>Patch</surname><given-names>A-M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wu J"><surname>Wu</surname><given-names>J</given-names></string-name>, <etal>et al.</etal> <year>2012</year>. <article-title hwp:id="article-title-4">Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes</article-title>. <source hwp:id="source-3">Nature</source> <volume>491</volume>: <fpage>399</fpage>â<lpage>405</lpage>.</citation></ref><ref id="c4" hwp:id="ref-4" hwp:rev-id="xref-ref-4-1 xref-ref-4-2 xref-ref-4-3 xref-ref-4-4 xref-ref-4-5"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Brooks AN"><surname>Brooks</surname><given-names>AN</given-names></string-name>, <string-name name-style="western" hwp:sortable="Choi PS"><surname>Choi</surname><given-names>PS</given-names></string-name>, <string-name name-style="western" hwp:sortable="de Waal L"><surname>de Waal</surname><given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sharifnia T"><surname>Sharifnia</surname><given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Imielinski M"><surname>Imielinski</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Saksena G"><surname>Saksena</surname><given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pedamallu CS"><surname>Pedamallu</surname><given-names>CS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sivachenko A"><surname>Sivachenko</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rosenberg M"><surname>Rosenberg</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chmielecki J"><surname>Chmielecki</surname><given-names>J</given-names></string-name>, <etal>et al.</etal> <year>2014</year>. <article-title hwp:id="article-title-5">A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic Mutations in U2AF1 Reveals Commonly Altered Splicing Events ed. G. Ast</article-title>. <source hwp:id="source-4">PLoS ONE</source> <volume>9</volume>: <fpage>e87361</fpage>.</citation></ref><ref id="c5" hwp:id="ref-5" hwp:rev-id="xref-ref-5-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Brosseau JP"><surname>Brosseau</surname><given-names>JP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lucier JF"><surname>Lucier</surname><given-names>JF</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lapointe E"><surname>Lapointe</surname><given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Durand M"><surname>Durand</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gendron D"><surname>Gendron</surname><given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gervais-Bird J"><surname>Gervais-Bird</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tremblay K"><surname>Tremblay</surname><given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Perreault JP"><surname>Perreault</surname><given-names>JP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Elela SA"><surname>Elela</surname><given-names>SA</given-names></string-name>. <year>2010</year>. <article-title hwp:id="article-title-6">High-throughput quantification of splicing isoforms</article-title>. <source hwp:id="source-5">RNA</source> <volume>16</volume>: <fpage>442</fpage>â<lpage>449</lpage>.</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><collab hwp:id="collab-1">Cancer Genome Atlas Network</collab>. <year>2012</year>. <article-title hwp:id="article-title-7">Comprehensive molecular portraits of human breast tumours</article-title>. <source hwp:id="source-6">Nature</source> <volume>490</volume>: <fpage>61</fpage>â<lpage>70</lpage>.</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1 xref-ref-7-2 xref-ref-7-3"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><collab hwp:id="collab-2">Cancer Genome Atlas Research Network</collab>. <year>2014</year>. <article-title hwp:id="article-title-8">Comprehensive molecular profiling of lung adenocarcinoma</article-title>. <source hwp:id="source-7">Nature</source> <volume>511</volume>: <fpage>543</fpage>â<lpage>550</lpage>.</citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.8" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Coulon A"><surname>Coulon</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ferguson ML"><surname>Ferguson</surname><given-names>ML</given-names></string-name>, <string-name name-style="western" hwp:sortable="de Turris V"><surname>de Turris</surname><given-names>V</given-names></string-name>, <string-name name-style="western" hwp:sortable="Palangat M"><surname>Palangat</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chow CC"><surname>Chow</surname><given-names>CC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Larson DR"><surname>Larson</surname><given-names>DR</given-names></string-name>. <year>2014</year>. <article-title hwp:id="article-title-9">Kinetic competition during the transcription cycle results in stochastic RNA processing</article-title>. <source hwp:id="source-8">Elife</source> <volume>3</volume>.</citation></ref><ref id="c9" hwp:id="ref-9" hwp:rev-id="xref-ref-9-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Fei DL"><surname>Fei</surname><given-names>DL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Li H"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kozul CD"><surname>Kozul</surname><given-names>CD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Black KE"><surname>Black</surname><given-names>KE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Singh S"><surname>Singh</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gosse JA"><surname>Gosse</surname><given-names>JA</given-names></string-name>, <string-name name-style="western" hwp:sortable="DiRenzo J"><surname>DiRenzo</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Martin KA"><surname>Martin</surname><given-names>KA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wang B"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hamilton JW"><surname>Hamilton</surname><given-names>JW</given-names></string-name>, <etal>et al.</etal> <year>2010</year>. <article-title hwp:id="article-title-10">Activation of Hedgehog signaling by the environmental toxicant arsenic may contribute to the etiology of arsenic-induced tumors</article-title>. <source hwp:id="source-9">Cancer Res</source> <volume>70</volume>: <fpage>1981</fpage>â<lpage>1988</lpage>.</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Fei DL"><surname>Fei</surname><given-names>DL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sanchez-Mejias A"><surname>Sanchez-Mejias</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wang Z"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Flaveny C"><surname>Flaveny</surname><given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Long J"><surname>Long</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Singh S"><surname>Singh</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rodriguez-Blanco J"><surname>Rodriguez-Blanco</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tokhunts R"><surname>Tokhunts</surname><given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Giambelli C"><surname>Giambelli</surname><given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Briegel KJ"><surname>Briegel</surname><given-names>KJ</given-names></string-name>, <etal>et al.</etal> <year>2012</year>. <article-title hwp:id="article-title-11">Hedgehog Signaling Regulates Bladder Cancer Growth and Tumorigenicity</article-title>. <source hwp:id="source-10">Cancer Res</source> <volume>72</volume>: <fpage>4449</fpage>â<lpage>4458</lpage>.</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Forbes SA"><surname>Forbes</surname><given-names>SA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Beare D"><surname>Beare</surname><given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gunasekaran P"><surname>Gunasekaran</surname><given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Leung K"><surname>Leung</surname><given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bindal N"><surname>Bindal</surname><given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Boutselakis H"><surname>Boutselakis</surname><given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ding M"><surname>Ding</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bamford S"><surname>Bamford</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cole C"><surname>Cole</surname><given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ward S"><surname>Ward</surname><given-names>S</given-names></string-name>, <etal>et al.</etal> <year>2015</year>. <article-title hwp:id="article-title-12">COSMIC: exploring the world's knowledge of somatic mutations in human cancer</article-title>. <source hwp:id="source-11">Nucleic Acids Res</source> <volume>43</volume>: <fpage>D805</fpage>â<lpage>11</lpage>.</citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Furney SJ"><surname>Furney</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pedersen M"><surname>Pedersen</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gentien D"><surname>Gentien</surname><given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dumont AG"><surname>Dumont</surname><given-names>AG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rapinat A"><surname>Rapinat</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Desjardins L"><surname>Desjardins</surname><given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Turajlic S"><surname>Turajlic</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Piperno-Neumann S"><surname>Piperno-Neumann</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="la Grange de P"><surname>la Grange de</surname><given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Roman-Roman S"><surname>Roman-Roman</surname><given-names>S</given-names></string-name>, <etal>et al.</etal> <year>2013</year>. <article-title hwp:id="article-title-13">SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma</article-title>. <source hwp:id="source-12">Cancer Discovery</source> <volume>3</volume>: <fpage>1122</fpage>â<lpage>1129</lpage>.</citation></ref><ref id="c13" hwp:id="ref-13" hwp:rev-id="xref-ref-13-1 xref-ref-13-2"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Graubert TA"><surname>Graubert</surname><given-names>TA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shen D"><surname>Shen</surname><given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ding L"><surname>Ding</surname><given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Okeyo-Owuor T"><surname>Okeyo-Owuor</surname><given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lunn CL"><surname>Lunn</surname><given-names>CL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shao J"><surname>Shao</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Krysiak K"><surname>Krysiak</surname><given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Harris CC"><surname>Harris</surname><given-names>CC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Koboldt DC"><surname>Koboldt</surname><given-names>DC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Larson DE"><surname>Larson</surname><given-names>DE</given-names></string-name>, <etal>et al.</etal> <year>2012</year>. <article-title hwp:id="article-title-14">Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes</article-title>. <source hwp:id="source-13">Nature Genetics</source> <volume>44</volume>: <fpage>53</fpage>â<lpage>57</lpage>.</citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1 xref-ref-14-2 xref-ref-14-3 xref-ref-14-4 xref-ref-14-5 xref-ref-14-6 xref-ref-14-7 xref-ref-14-8"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Ilagan JO"><surname>Ilagan</surname><given-names>JO</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ramakrishnan A"><surname>Ramakrishnan</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hayes B"><surname>Hayes</surname><given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Murphy ME"><surname>Murphy</surname><given-names>ME</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zebari AS"><surname>Zebari</surname><given-names>AS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bradley P"><surname>Bradley</surname><given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bradley RK"><surname>Bradley</surname><given-names>RK</given-names></string-name>. <year>2015</year>. <article-title hwp:id="article-title-15">U2AF1 mutations alter splice site recognition in hematological malignancies</article-title>. <source hwp:id="source-14">Genome Res</source> <volume>25</volume>: <fpage>14</fpage>â<lpage>26</lpage>.</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1 xref-ref-15-2"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Imielinski M"><surname>Imielinski</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Berger AH"><surname>Berger</surname><given-names>AH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hammerman PS"><surname>Hammerman</surname><given-names>PS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hernandez B"><surname>Hernandez</surname><given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pugh TJ"><surname>Pugh</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hodis E"><surname>Hodis</surname><given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cho J"><surname>Cho</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Suh J"><surname>Suh</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Capelletti M"><surname>Capelletti</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sivachenko A"><surname>Sivachenko</surname><given-names>A</given-names></string-name>, <etal>et al.</etal> <year>2012</year>. <article-title hwp:id="article-title-16">Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing</article-title>. <source hwp:id="source-15">Cell</source> <volume>150</volume>: <fpage>1107</fpage>â<lpage>1120</lpage>.</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Kralovicova J"><surname>Kralovicova</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Vorechovsky I"><surname>Vorechovsky</surname><given-names>I</given-names></string-name>. <year>2010</year>. <article-title hwp:id="article-title-17">Allele-specific recognition of the 3' splice site of INS intron 1</article-title>. <source hwp:id="source-16">Hum Genet</source> <volume>128</volume>: <fpage>383</fpage>â<lpage>400</lpage>.</citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="KrÃ¤mer A"><surname>KrÃ¤mer</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Utans U"><surname>Utans</surname><given-names>U</given-names></string-name>. <year>1991</year>. <article-title hwp:id="article-title-18">Three protein factors (SF1, SF3 and U2AF) function in presplicing complex formation in addition to snRNPs</article-title>. <source hwp:id="source-17">The EMBO Journal</source> <volume>10</volume>: <fpage>1503</fpage>â<lpage>1509</lpage>.</citation></ref><ref id="c18" hwp:id="ref-18" hwp:rev-id="xref-ref-18-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.18" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="Lee SC-W"><surname>Lee</surname><given-names>SC-W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dvinge H"><surname>Dvinge</surname><given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kim E"><surname>Kim</surname><given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cho H"><surname>Cho</surname><given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Micol J-B"><surname>Micol</surname><given-names>J-B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chung YR"><surname>Chung</surname><given-names>YR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Durham BH"><surname>Durham</surname><given-names>BH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yoshimi A"><surname>Yoshimi</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kim YJ"><surname>Kim</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Thomas M"><surname>Thomas</surname><given-names>M</given-names></string-name>, <etal>et al.</etal> <year>2016</year>. <article-title hwp:id="article-title-19">Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins</article-title>. <source hwp:id="source-18">Nat Med.</source></citation></ref><ref id="c19" hwp:id="ref-19" hwp:rev-id="xref-ref-19-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.19" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Liu Z"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Luyten I"><surname>Luyten</surname><given-names>I</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bottomley MJ"><surname>Bottomley</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Messias AC"><surname>Messias</surname><given-names>AC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Houngninou-Molango S"><surname>Houngninou-Molango</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sprangers R"><surname>Sprangers</surname><given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zanier K"><surname>Zanier</surname><given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="KrÃ¤mer A"><surname>KrÃ¤mer</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sattler M"><surname>Sattler</surname><given-names>M</given-names></string-name>. <year>2001</year>. <article-title hwp:id="article-title-20">Structural basis for recognition of the intron branch site RNA by splicing factor 1</article-title>. <source hwp:id="source-19">Science</source> <volume>294</volume>: <fpage>1098</fpage>â<lpage>1102</lpage>.</citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.20" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Lu G"><surname>Lu</surname><given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hall TMT"><surname>Hall</surname><given-names>TMT</given-names></string-name>. <year>2011</year>. <article-title hwp:id="article-title-21">Alternate modes of cognate RNA recognition by human PUMILIO proteins</article-title>. <source hwp:id="source-20">Structure</source> <volume>19</volume>: <fpage>361</fpage>â<lpage>367</lpage>.</citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="Merendino L"><surname>Merendino</surname><given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Guth S"><surname>Guth</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bilbao D"><surname>Bilbao</surname><given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Martmez C"><surname>Martmez</surname><given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="ValcÃ¡rcel J"><surname>ValcÃ¡rcel</surname><given-names>J</given-names></string-name>. <year>1999</year>. <article-title hwp:id="article-title-22">Inhibition of msl-2 splicing by Sex-lethal reveals interaction between U2AF35 and the 3' splice site AG</article-title>. <source hwp:id="source-21">Nature</source> <volume>402</volume>: <fpage>838</fpage>â<lpage>841</lpage>.</citation></ref><ref id="c22" hwp:id="ref-22" hwp:rev-id="xref-ref-22-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.22" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Miller MT"><surname>Miller</surname><given-names>MT</given-names></string-name>, <string-name name-style="western" hwp:sortable="Higgin JJ"><surname>Higgin</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hall TMT"><surname>Hall</surname><given-names>TMT</given-names></string-name>. <year>2008</year>. <article-title hwp:id="article-title-23">Basis of altered RNA-binding specificity by PUF proteins revealed by crystal structures of yeast Puf4p</article-title>. <source hwp:id="source-22">Nat Struct Mol Biol</source> <volume>15</volume>: <fpage>397</fpage>â<lpage>402</lpage>.</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1 xref-ref-23-2 xref-ref-23-3 xref-ref-23-4 xref-ref-23-5 xref-ref-23-6 xref-ref-23-7 xref-ref-23-8 xref-ref-23-9 xref-ref-23-10 xref-ref-23-11"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Okeyo-Owuor T"><surname>Okeyo-Owuor</surname><given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="White BS"><surname>White</surname><given-names>BS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chatrikhi R"><surname>Chatrikhi</surname><given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mohan DR"><surname>Mohan</surname><given-names>DR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kim S"><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Griffith M"><surname>Griffith</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ding L"><surname>Ding</surname><given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ketkar-Kulkarni S"><surname>Ketkar-Kulkarni</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hundal J"><surname>Hundal</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Laird KM"><surname>Laird</surname><given-names>KM</given-names></string-name>, <etal>et al.</etal> <year>2015</year>. <article-title hwp:id="article-title-24">U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing</article-title>. <source hwp:id="source-23">Leukemia</source> <volume>29</volume>: <fpage>909</fpage>â<lpage>917</lpage>.</citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1 xref-ref-24-2"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.24" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Park SM"><surname>Park</surname><given-names>SM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ou J"><surname>Ou</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chamberlain L"><surname>Chamberlain</surname><given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Simone TM"><surname>Simone</surname><given-names>TM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yang H"><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Virbasius C-M"><surname>Virbasius</surname><given-names>C-M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ali AM"><surname>Ali</surname><given-names>AM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhu LJ"><surname>Zhu</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mukherjee S"><surname>Mukherjee</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Raza A"><surname>Raza</surname><given-names>A</given-names></string-name>, <etal>et al.</etal> <year>2016</year>. <article-title hwp:id="article-title-25">U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3</article-title>. <source hwp:id="source-24">Mol Cell</source> <fpage>1</fpage>â<lpage>34</lpage>.</citation></ref><ref id="c25" hwp:id="ref-25" hwp:rev-id="xref-ref-25-1 xref-ref-25-2 xref-ref-25-3 xref-ref-25-4"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.25" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="Przychodzen B"><surname>Przychodzen</surname><given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jerez A"><surname>Jerez</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Guinta K"><surname>Guinta</surname><given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sekeres MA"><surname>Sekeres</surname><given-names>MA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Padgett R"><surname>Padgett</surname><given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Maciejewski JP"><surname>Maciejewski</surname><given-names>JP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Makishima H"><surname>Makishima</surname><given-names>H</given-names></string-name>. <year>2013</year>. <article-title hwp:id="article-title-26">Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms</article-title>. <source hwp:id="source-25">Blood</source> <volume>122</volume>: <fpage>999</fpage>â<lpage>1006</lpage>.</citation></ref><ref id="c26" hwp:id="ref-26" hwp:rev-id="xref-ref-26-1 xref-ref-26-2"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.26" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Ramirez RD"><surname>Ramirez</surname><given-names>RD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sheridan S"><surname>Sheridan</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Girard L"><surname>Girard</surname><given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sato M"><surname>Sato</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kim Y"><surname>Kim</surname><given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pollack J"><surname>Pollack</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Peyton M"><surname>Peyton</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zou Y"><surname>Zou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kurie JM"><surname>Kurie</surname><given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dimaio JM"><surname>Dimaio</surname><given-names>JM</given-names></string-name>, <etal>et al.</etal> <year>2004</year>. <article-title hwp:id="article-title-27">Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins</article-title>. <source hwp:id="source-26">Cancer Res</source> <volume>64</volume>: <fpage>9027</fpage>â<lpage>9034</lpage>.</citation></ref><ref id="c27" hwp:id="ref-27" hwp:rev-id="xref-ref-27-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Ruskin B"><surname>Ruskin</surname><given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zamore PD"><surname>Zamore</surname><given-names>PD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Green MR"><surname>Green</surname><given-names>MR</given-names></string-name>. <year>1988</year>. <article-title hwp:id="article-title-28">A factor, U2AF, is required for U2 snRNP binding and splicing complex assembly</article-title>. <source hwp:id="source-27">Cell</source> <volume>52</volume>: <fpage>207</fpage>â<lpage>219</lpage>.</citation></ref><ref id="c28" hwp:id="ref-28" hwp:rev-id="xref-ref-28-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.28" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-28"><string-name name-style="western" hwp:sortable="Shao C"><surname>Shao</surname><given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yang B"><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wu T"><surname>Wu</surname><given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Huang J"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tang P"><surname>Tang</surname><given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhou Y"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhou J"><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Qiu J"><surname>Qiu</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jiang L"><surname>Jiang</surname><given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Li H"><surname>Li</surname><given-names>H</given-names></string-name>, <etal>et al.</etal> <year>2014</year>. <article-title hwp:id="article-title-29">Mechanisms for U2AF to define 3' splice sites and regulate alternative splicing in the human genome</article-title>. <source hwp:id="source-28">Nat Struct Mol Biol</source> <volume>21</volume>: <fpage>997</fpage>â<lpage>1005</lpage>.</citation></ref><ref id="c29" hwp:id="ref-29" hwp:rev-id="xref-ref-29-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.29" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-29"><string-name name-style="western" hwp:sortable="Shirai CL"><surname>Shirai</surname><given-names>CL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ley JN"><surname>Ley</surname><given-names>JN</given-names></string-name>, <string-name name-style="western" hwp:sortable="White BS"><surname>White</surname><given-names>BS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kim S"><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tibbitts J"><surname>Tibbitts</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shao J"><surname>Shao</surname><given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ndonwi M"><surname>Ndonwi</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wadugu B"><surname>Wadugu</surname><given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Duncavage EJ"><surname>Duncavage</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Okeyo-Owuor T"><surname>Okeyo-Owuor</surname><given-names>T</given-names></string-name>, <etal>et al.</etal> <year>2015</year>. <article-title hwp:id="article-title-30">Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo</article-title>. <source hwp:id="source-29">Cancer Cell</source> <volume>27</volume>: <fpage>631</fpage>â<lpage>643</lpage>.</citation></ref><ref id="c30" hwp:id="ref-30" hwp:rev-id="xref-ref-30-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.30" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-30"><string-name name-style="western" hwp:sortable="Wang L"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lawrence MS"><surname>Lawrence</surname><given-names>MS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wan Y"><surname>Wan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stojanov P"><surname>Stojanov</surname><given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sougnez C"><surname>Sougnez</surname><given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stevenson K"><surname>Stevenson</surname><given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Werner L"><surname>Werner</surname><given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sivachenko A"><surname>Sivachenko</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="DeLuca DS"><surname>DeLuca</surname><given-names>DS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhang L"><surname>Zhang</surname><given-names>L</given-names></string-name>, <etal>et al.</etal> <year>2011</year>. <article-title hwp:id="article-title-31">SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia</article-title>. <source hwp:id="source-30">N Engl J Med</source> <volume>365</volume>: <fpage>2497</fpage>â<lpage>2506</lpage>.</citation></ref><ref id="c31" hwp:id="ref-31" hwp:rev-id="xref-ref-31-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.31" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-31"><string-name name-style="western" hwp:sortable="Waterfall JJ"><surname>Waterfall</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Arons E"><surname>Arons</surname><given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Walker RL"><surname>Walker</surname><given-names>RL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pineda M"><surname>Pineda</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Roth L"><surname>Roth</surname><given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Killian JK"><surname>Killian</surname><given-names>JK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Abaan OD"><surname>Abaan</surname><given-names>OD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Davis SR"><surname>Davis</surname><given-names>SR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kreitman RJ"><surname>Kreitman</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Meltzer PS"><surname>Meltzer</surname><given-names>PS</given-names></string-name>. <year>2014</year>. <article-title hwp:id="article-title-32">High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias</article-title>. <source hwp:id="source-31">Nature Genetics</source> <volume>46</volume>: <fpage>8</fpage>â<lpage>10</lpage>.</citation></ref><ref id="c32" hwp:id="ref-32" hwp:rev-id="xref-ref-32-1 xref-ref-32-2"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.32" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-32"><string-name name-style="western" hwp:sortable="Wu S"><surname>Wu</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Romfo CM"><surname>Romfo</surname><given-names>CM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nilsen TW"><surname>Nilsen</surname><given-names>TW</given-names></string-name>, <string-name name-style="western" hwp:sortable="Green MR"><surname>Green</surname><given-names>MR</given-names></string-name>. <year>1999</year>. <article-title hwp:id="article-title-33">Functional recognition of the 3' splice site AG by the splicing factor U2AF35</article-title>. <source hwp:id="source-32">Nature</source> <volume>402</volume>: <fpage>832</fpage>â<lpage>835</lpage>.</citation></ref><ref id="c33" hwp:id="ref-33" hwp:rev-id="xref-ref-33-1 xref-ref-33-2"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.33" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-33"><string-name name-style="western" hwp:sortable="Yoshida H"><surname>Yoshida</surname><given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Park S-Y"><surname>Park</surname><given-names>S-Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Oda T"><surname>Oda</surname><given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Akiyoshi T"><surname>Akiyoshi</surname><given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sato M"><surname>Sato</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shirouzu M"><surname>Shirouzu</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tsuda K"><surname>Tsuda</surname><given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kuwasako K"><surname>Kuwasako</surname><given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Unzai S"><surname>Unzai</surname><given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Muto Y"><surname>Muto</surname><given-names>Y</given-names></string-name>, <etal>et al.</etal> <year>2015</year>. <article-title hwp:id="article-title-34">A novel 3' splice site recognition by the two zinc fingers in the U2AF small subunit</article-title>. <source hwp:id="source-33">Genes &amp; Development</source> <volume>29</volume>: <fpage>1649</fpage>â<lpage>1660</lpage>.</citation></ref><ref id="c34" hwp:id="ref-34" hwp:rev-id="xref-ref-34-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.34" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-34"><string-name name-style="western" hwp:sortable="Yoshida K"><surname>Yoshida</surname><given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sanada M"><surname>Sanada</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shiraishi Y"><surname>Shiraishi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nowak D"><surname>Nowak</surname><given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nagata Y"><surname>Nagata</surname><given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yamamoto R"><surname>Yamamoto</surname><given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sato Y"><surname>Sato</surname><given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sato-Otsubo A"><surname>Sato-Otsubo</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kon A"><surname>Kon</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nagasaki M"><surname>Nagasaki</surname><given-names>M</given-names></string-name>, <etal>et al.</etal> <year>2011</year>. <article-title hwp:id="article-title-35">Frequent pathway mutations of splicing machinery in myelodysplasia</article-title>. <source hwp:id="source-34">Nature</source> <volume>478</volume>: <fpage>64</fpage>â<lpage>69</lpage>.</citation></ref><ref id="c35" hwp:id="ref-35" hwp:rev-id="xref-ref-35-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.35" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-35"><string-name name-style="western" hwp:sortable="Yusa K"><surname>Yusa</surname><given-names>K</given-names></string-name>. <year>2013</year>. <article-title hwp:id="article-title-36">Seamless genome editing in human pluripotent stem cells using custom endonuclease-based gene targeting and the piggyBac transposon</article-title>. <source hwp:id="source-35">Nat Protoc</source> <volume>8</volume>: <fpage>2061</fpage>â<lpage>2078</lpage>.</citation></ref><ref id="c36" hwp:id="ref-36" hwp:rev-id="xref-ref-36-1"><citation publication-type="confproc" citation-type="confproc" ref:id="048553v4.36" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-36"><string-name name-style="western" hwp:sortable="Zamore PD"><surname>Zamore</surname><given-names>PD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Green MR"><surname>Green</surname><given-names>MR</given-names></string-name>. <conf-date>1989</conf-date>. <article-title hwp:id="article-title-37">Identification, purification, and biochemical characterization of U2 small nuclear ribonucleoprotein auxiliary factor</article-title>. <conf-name>Proc Natl Acad Sci</conf-name> <conf-date>U S A</conf-date> <volume>86</volume>: <fpage>9243</fpage>â<lpage>9247</lpage>.</citation></ref><ref id="c37" hwp:id="ref-37" hwp:rev-id="xref-ref-37-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.37" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-37"><string-name name-style="western" hwp:sortable="Zhou Q"><surname>Zhou</surname><given-names>Q</given-names></string-name>, <string-name name-style="western" hwp:sortable="Derti A"><surname>Derti</surname><given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ruddy D"><surname>Ruddy</surname><given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rakiec D"><surname>Rakiec</surname><given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kao I"><surname>Kao</surname><given-names>I</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lira M"><surname>Lira</surname><given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gibaja V"><surname>Gibaja</surname><given-names>V</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chan H"><surname>Chan</surname><given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yang Y"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Min J"><surname>Min</surname><given-names>J</given-names></string-name>, <etal>et al.</etal> <year>2015</year>. <article-title hwp:id="article-title-38">A Chemical Genetics Approach for the Functional Assessment of Novel Cancer Genes</article-title>. <source hwp:id="source-36">Cancer Res</source> <volume>75</volume>: <fpage>1949</fpage>â<lpage>1958</lpage>.</citation></ref><ref id="c38" hwp:id="ref-38" hwp:rev-id="xref-ref-38-1"><citation publication-type="journal" citation-type="journal" ref:id="048553v4.38" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-38"><string-name name-style="western" hwp:sortable="Zorio DA"><surname>Zorio</surname><given-names>DA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Blumenthal T"><surname>Blumenthal</surname><given-names>T</given-names></string-name>. <year>1999</year>. <article-title hwp:id="article-title-39">Both subunits of U2AF recognize the 3' splice site in Caenorhabditis elegans</article-title>. <source hwp:id="source-37">Nature</source> <volume>402</volume>: <fpage>835</fpage>â<lpage>838</lpage>.</citation></ref></ref-list></back></article>
